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Regulation of Papillomavirus E2 Protein by Post-translational Modification 
Papillomaviruses (PVs) are small, double-stranded DNA viruses. Hundreds 
of species have evolved to replicate in mammals, birds, and reptiles. 
Approximately two hundred species are estimated to infect humans alone, and 
these human papillomaviruses (HPVs) cause diseases ranging from benign warts 
to anogenital and oropharyngeal cancers.  While vaccination is effective at 
preventing the majority of these infections and their disease outcomes, there are 
no successful treatments for existing infections; thus, exploration of novel 
therapeutic targets is warranted. 
PVs control expression and function of their gene products through alternative 
splicing, alternate start codons, and post-translational modification (PTM). The 
viral E2 protein regulates transcription, replication, and genome maintenance in 
infected cells, and PTMs have been demonstrated for E2 proteins from multiple 
papillomavirus types. Serine phosphorylation events were reported to influence E2 
stability, and our laboratory was the first to describe in vitro acetylation events with 
implications for E2 transcription function. Here we report confirmation of these 
acetylation events in vivo and additional data elucidating the role of these PTMs in 
viral transcription. Moreover, we present a novel phosphorylation site for bovine 
papillomavirus type 1 (BPV-1) E2 at tyrosine 102 (Y102).  Using phospho-deficient 
and phospho-mimetic point mutants, we found that this site influences E2-
mediated transcription and replication, and we hypothesize that phosphorylation 
at Y102 regulates these activities by interrupting the association of E2                    
v 
with its binding partners. We also report interaction of BPV-1 E2 and HPV-31 E2 
with different receptor tyrosine kinases (TKs), most notably members of the 
fibroblast growth factor receptor family. We hypothesize that Y102 phosphorylation 
by these receptors occurs early in infection to limit viral replication and gene 
expression. Further studies will cement the role of RTKs in PV biology and could 
reveal novel therapeutic strategies. 
 
Elliot Androphy, M.D., Chair 
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CHAPTER 1 
INTRODUCTION 
 
*Note: A portion of this work was published in Culleton SP, Androphy EJ, 
Kanginakudru S. Papillomavirus Replication. HPV-Associated Oropharyngeal 
Cancer. Ed. MS Stack and DL Miller. Springer, September 2015. 
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Human Papillomaviruses and Disease 
HPV is the most common sexually transmitted infection in the United 
States. According to the Centers for Disease Control and Prevention, 79 million 
Americans are currently infected with at least one type of HPV, and most 
sexually active Americans will have at least one HPV infection during their 
lifetime (cdc.gov/std/hpv). There are at least two hundred types of human 
papillomaviruses (HPVs). Different HPV types are associated with different 
disease outcomes, ranging from genital warts (condyloma acuminata) caused 
by HPV-6 and HPV-11 to the cancers caused by HPV-16 and HPV-18. These 
two types, classified as “high-risk” due to their oncogenic potential, are the two 
most common HPVs implicated in cervical cancer, causing an estimated 70% 
of all cases (Guilfoile and Babcock, 2012). These and other high-risk types such 
as HPV-31 have also been detected in oropharyngeal cancers (Michaud et al., 
2014). Persistent infection with a high-risk HPV is a causative factor in almost 
all cases of cervical cancer as well as other anogenital cancers. 
Although cervical cancer was once one of the top causes of cancer-
related death in America, the addition of the Papanicolaou (Pap) smear for 
cervical dysplasia screening to routine physical exams reduced incidence and 
deaths from this disease by 60% in less than 40 years 
(report.nih.gov/nihfactsheets). Even more promising for eliminating cervical 
cancer is the introduction of the HPV vaccines Gardasil and Cervarix in the 
early 2000s. These vaccines, which consist of virus-like particles (VLPs) made 
from L1 protein of specific HPV types (6, 11, 16, and 18 for Gardasil, 16 and 18 
for Cervarix), are nearly 100% effective at preventing HPV infection. This 
means that Gardasil will theoretically eliminate the 70% of cervical cancer 
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cases caused by HPV-16 and 18 as well as the 90% of genital warts cases 
caused by HPV-6 and 11 (report.nih.gov/nihfactsheets). 
Despite the significant benefits provided by vaccination, there is 
currently no treatment for the tens of millions of existing HPV infections. About 
90% of HPV infections are estimated to clear spontaneously within two years, 
but the few that persist beyond this point can cause cellular anomalies that lead 
to cancer (who.int/mediacentre/factsheets). Currently, because it can take 
decades to progress from the initial infection to cancer, regular Pap smears and 
prompt removal of pre-cancerous cervical dysplasias are the best option for 
avoiding complications of HPV infection. Even more preferable would be 
treatment to eradicate HPV infection in its early stages, before signs of cellular 
abnormalities occur. Further study into the processes that control infection is 
therefore necessary to identify potential therapeutic targets. 
 
Papillomavirus Structure and Taxonomy 
Papillomaviruses (PVs) comprise a family of hundreds of non-enveloped 
DNA viruses which infect mammals, birds, or reptiles. All PVs are divided into 
genera (designated with Greek letters) based on sequence variations in the L1 
gene. For example, the α-PVs include HPVs that infect either mucosal or 
cutaneous keratinocytes and can be further divided into high- or low-risk types 
based on their ability to immortalize infected cells. In contrast, β-PVs 
preferentially infect cutaneous epithelium (de Villiers et al., 2004) and cause 
cutaneous malignancies in immunosuppressed individuals (Doorbar et al., 
2015), including patients with the rare skin disorder epidermodysplasia 
verruciformis (EV). 
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PVs contain a double-stranded, circular DNA genome about 8 kilobases 
(kb) in length. The bovine papillomavirus type 1 (BPV-1) genome shown in 
Figure 1.1 contains coding regions for six early genes (E1-E8) and two late 
genes (L1 and L2), as well as a non-coding upstream regulatory region (URR, 
or long control region, LCR) that includes the viral origin of replication (ori) and 
the minichromosome maintenance element (MME), which facilitates efficient 
viral genome partitioning in dividing host cells. Certain PVs also produce splice 
variants of the major genes, including E8^E2, E1^E4, and a group of splice 
products from within the E6 gene collectively designated E6*. 
In BPV-1, a widely used model for papillomavirus research, there are 
two major classes of promoter that drive expression from the genome. Early 
promoters (major promoter: P89; see Figure 1.1) regulate transcription of the 
early gene products with the involvement of several host transcription factors 
such as nuclear factor I (NF-I) (Gloss et al., 1989), activator protein 1 (AP-1) 
(Offord and Beard, 1990), specificity protein 1 (SP1) (Gloss and Bernard, 1990), 
and the transcription factor II-D (TFIID) complex (Carrillo et al., 2004). 
Regulation of the early promoter has been found at least in part to be 
differentiation-dependent; in infected cells, early gene transcripts are more 
abundant in differentiated cells than in undifferentiated cells (Yukawa et al., 
1996, Durst et al., 1992, O'Connor et al., 2000). Differential regulation of other 
promoters (i.e. P2443 and P3080; see Figure 1.1) also modulates early promoter 
function (Linz and Baker, 1988). The late promoter PL is active only in 
differentiating cells such as those found in fibropapillomas (warts) (Linz and 
Baker, 1988), and its regulation is not as well understood. It controls expression 
of the capsid proteins in preparation for virion assembly and exit from host cells. 
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FIGURE 1.1 
Figure 1.1. The bovine papillomavirus type 1 (BPV-1) genome. The 
papillomavirus genome is comprised of circular, double-stranded DNA 
approximately 8 kilobases (kb) in length. BPV-1 encodes several early 
genes (E1-E8; curved lines are scaled to length of open reading frames 
(ORFs)) and two late genes (L1 and L2). The transcription and replication 
factor E2 has several binding sites in the genome with the consensus 
sequence ACC(N6)GGT (black dots). The long control region (LCR), also 
called the upstream regulatory region (URR), is a large region of noncoding 
DNA containing the origin of replication (ori, bar) and the minichromosome 
maintenance element (MME, two-headed arrow). Transcription is initiated 
from several promoters (bent arrows), including the major early promoter 
P89, the late promoter PL, and the regulatory promoters P2443 and P3080 (Linz 
and Baker, 1988). Reprinted with permission from (Skiadopoulos and 
McBride, 1998). 
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Infection and Entry 
PVs preferentially infect keratinocytes in the basal layer of the 
epithelium. They gain access to these cells by means of microscopic abrasions 
or lesions which expose the basement membrane (Figure 1.2). PVs are thought 
to bind the basement membrane rather than basal keratinocytes themselves 
(Roberts et al., 2007). Viral particles primarily bind to heparan sulfate 
proteoglycans (HSPGs) (Shafti-Keramat et al., 2003), though other proteins 
such as laminin-332 may also aid in viral attachment (Cerqueira et al., 2013). 
Studies using pseudovirions (comprised of L1, L2, and reporter DNA such as 
the GFP gene) have shown that HSPG binding causes a conformational 
change in L2 which exposes a furin protease cleavage site. Furin cleavage is 
necessary for subsequent conformational changes which allow binding to an as 
yet unidentified cell surface receptor (Kines et al., 2009). Viral entry occurs 12-
24 hours after binding (Culp and Christensen, 2004). 
PVs are internalized by different mechanisms depending on viral type. 
HPV-31 and bovine papillomavirus type 1 (BPV-1) seem to depend on clathrin 
and caveolin for their entry into cells (Raff et al., 2013, Horvath et al., 2010). 
HPV-16, however, employs actin-dependent endocytosis initiated by the 
phosphoinositide 3-kinase (PI3K) pathway (Surviladze et al., 2013) 
Interestingly, PI3K is emerging as a potential therapeutic target  for head and 
neck squamous cell carcinoma (HNSCC) (Yap et al., 2008). The PI3K encoding 
gene PIK3CA acquires an activating mutation in HPV-positive head and neck 
cancers (Lui et al., 2013). A study using HPV-16 pseudovirus (PsV) to study 
viral entry mechanisms revealed that the small-molecule PI3K inhibitor 
LY294002 prevented the majority of PsV infection of HaCaT cells (immortalized 
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keratinocytes) (Surviladze et al., 2013), and another study reported that siRNA 
against PI3K prevents E6 and E7 mediated Akt signaling downstream of the 
kinase (Zhang et al., 2014a). 
Once the virus is internalized, it enters the endosomal pathway, where 
the major capsid protein L1 dissociates from the L2-DNA complex. Retrograde 
transport of this complex from the Golgi to the ER by a γ-secretase-dependent 
mechanism has been suggested as a means of getting viral DNA close to the 
nucleus (Zhang et al., 2014b). Actin filaments may also assist in L2-DNA 
nuclear transport (Schelhaas et al., 2012), though it is thought that PV DNA 
enters the nucleus after cell division as the nuclear envelope re-forms (McBride, 
2008). Once viral DNA arrives in the nucleus, it associates with promyelocytic 
leukemia protein (PML) complexes, called PML bodies, to initiate transcription 
and replication (Day et al., 2004). The factors required to first express and 
maintain the early proteins in the host are unknown. 
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FIGURE 1.2 
 
 
 
Figure 1.2. Viral infection and replicative cycle in the context of the 
keratinized epithelium. Papillomavirus gains access to the basal layer of 
the keratinized epithelium (pale cells, keratinocytes; brown cell, melanocyte) 
via micro-abrasions (red bolt). The virus establishes its copy number in the 
basal cells (green rings, bottom cell layers). As host cells migrate upward 
and differentiate, viral genome copy number is amplified (green rings, top 
cell layers). Amplification prepares cells to produce new viral particles 
(green polygons), which are released into the environment as dead cells 
slough off the epithelial surface. 
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Replicative Cycle 
PV replication requires complex crosstalk between viral and cellular 
proteins across the different life phases of the host cell, from proliferation and 
maturation to differentiation and death. There are three major stages in the viral 
replicative cycle: initiation, maintenance, and amplification. Each one requires 
PVs to exploit cellular resources available at different times in keratinocyte 
development. 
In the initial stage of PV replication, the genome is copied at a low level, 
usually between 1 and 10 copies per cell depending on the system used for 
study (Chesters and McCance, 1985, Botchan et al., 1986, Geimanen et al., 
2011). The viral helicase E1 and the replication and transcription regulator E2 
are required for PV replication. E2 recruits E1, which binds viral DNA with low 
specificity, to the viral origin of replication (ori) (Ustav and Stenlund, 1991) 
(Figure 1.3). The E2:E1 interaction is transient, however, since E2 must 
dissociate for E1 to form a double hexamer and initiate replication (Sanders 
and Stenlund, 1998, Abbate et al., 2004). The cellular factors that contribute to 
viral replication include: DNA polymerase (Pol) α, Pol δ, RPA, and 
topoisomerases (Topos) I and II. All of these factors were required for 
replication in a cell-free system (Kuo et al., 1994), withTopo I acting similarly to 
E2 in recruiting E1 to the ori before dissociating (Hu et al., 2006). 
After initial replication, PVs enter their maintenance stage. When an 
infected cell divides, PV genome copies are passed on to the daughter cells via 
interaction of E2-DNA complexes with cellular proteins. Some of these proteins, 
including Brd4 (You et al., 2004) and Chlr1 (Parish et al., 2006), tether the 
complexes to host chromosomes, while others such as Mklp2 mediate 
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interaction with the mitotic spindle (Van Tine et al., 2004, Yu et al., 2007). 
During maintenance replication, the majority of E1 protein is sequestered in the 
cytoplasm (Fradet-Turcotte et al., 2010a), likely because high amounts of 
nuclear E1 are toxic to cells (Sakakibara et al., 2013). Expression of E1 and E2 
is low at this time, which limits replication activity (Lambert, 1991) and may be 
controlled by the E6 and E7 proteins, though the exact mechanism is unknown. 
Stable maintenance of HPV episomes (versus integration) depends on E6 and 
E7 (Thomas et al., 1999), particularly the p53 degradation function of E6 (Park 
and Androphy, 2002). While PVs can maintain their genomes strictly in the 
episomal form, BPV-1 genomes in the ID13 cell line (mouse fibroblasts stably 
expressing BPV-1) were detected as monomeric episomes as well as tandem 
repeats integrated within host chromosomes (Schvartzman et al., 1990). 
Multimeric episomes have also been observed in cell lines and patient samples 
(Kennedy et al., 1987, Choo et al., 1989, Kristiansen et al., 1994, Orav et al., 
2013). 
Keratinocytes terminally differentiate as they migrate towards the 
epithelial surface. In infected cells, in a process that is not fully understood, PVs 
sense and exploit cellular differentiation to transition to the amplification stage 
of their replication cycle. In this stage, PV genome copy number increases to 
thousands of copies per cell. The DNA damage response pathway (DDR) 
assists in amplification (Gillespie et al., 2012): activation of one branch of the 
DDR, the ATM pathway, recruits DNA damage proteins to viral replication 
centers in the nucleus (Moody and Laimins, 2009). Multiple factors that 
stimulate amplification do so through activating the DDR; these include 
chemical and biological mutagens (Schmitt et al., 1989) and the viral E7 
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oncoprotein (Hong and Laimins, 2013). 
E7 as well as the E6 oncoprotein promotes amplification by preventing 
complete cell-cycle arrest, allowing the virus to utilize host replication 
machinery despite activation of DNA repair pathways (Gillespie et al., 2012). 
The E5 oncoprotein has also been shown to promote amplification (McBride, 
2008). While most PVs manipulate their hosts only to the extent needed for viral 
propagation, the high-risk HPVs can undergo aberrant replication which has 
mutagenic effects on the host cell. They integrate their genomes into host cell 
chromosomes, abrogating virion production while further dysregulating cell 
cycle arrest and DNA repair. Since integration usually disrupts the E2 gene, 
which is responsible for limiting expression of E6 and E7, these oncoproteins 
can act unchecked. Inhibiting the tumor suppressors p53 and Rb, they produce 
genomic instability leading to neoplastic changes and progression to cancer 
(Shin et al., 2006a, Shin et al., 2006b). In the context of cervical cancer, both 
integration and the absence of an intact E2 gene (i.e. from episomal HPV DNA 
co-existing with integrated DNA in the same cell) are associated with poor 
prognosis (Shin et al., 2014). 
We hypothesize that there is a means to limit E2 function even before 
loss of the gene through integration. Generally, we assert that post-translational 
modification of viral proteins contributes to the coordinated timing of the viral 
replicative cycle with the different stages of the host-cell life cycle. The next 
section and the following chapters build a case for E2 as a crucial recipient of 
this form of regulation because it is a highly conserved protein of diverse 
functions. 
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FIGURE 1.3 
 
 
 
Figure 1.3. Recruitment of the viral helicase E1 to DNA by the E2 
protein. E2 (orange oval) binds with high specificity to the consensus 
sequence ACC(N6)GGT (E2BS, blue box). When E2 binds these sites in the 
ori (Figure 1.1), it can recruit E1 monomers (green ovals) to efficiently 
assemble on DNA (E1 binds the ori with low specificity in the absence of 
E2). After E1 forms a double hexamer (hence “12 x” E1) and E2 dissociates, 
cellular replication factors bind and assist E1 in initiating replication. 
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E2: Structure and Functions 
E2 is a modular protein containing two distinct domains, an amino-
terminal transactivating domain (TAD) and a carboxy-terminal DNA-binding 
domain (DBD) (Figure 1.4), which are highly conserved among PVs (Giri and 
Yaniv, 1988). The two domains are connected by a less conserved, flexible 
hinge region. In BPV-1 E2, which is 410 amino acids (aa) in length and 48 
kilodaltons (kDa) in mass, aa 1-216 comprise the TAD and aa 286-410 
comprise the DBD. 
E2 monomers interact at their DBDs to form an 8-stranded antiparallel β 
barrel which interacts with DNA, and each monomer also contributes α helices 
outside the barrel to enhance sequence-specific binding interactions (Hegde et 
al., 1992, Hegde and Androphy, 1998, Hegde, 2002). The β barrel binds the 
palindromic DNA consensus sequence ACC(N6)GGT (Androphy et al., 1987, 
Hegde, 2002).The identity of the variable bases in each E2 binding site (E2BS) 
determines the affinity of E2 for that site, and both high- and low-affinity E2BS 
are found in the viral upstream regulatory region (URR) (Figure 1.1). E2 
association with high-affinity E2BS results in transcriptional activation, while 
association with low-affinity E2BS results in transcriptional repression and 
replication (Hegde, 2002). Thus, viral gene transcription (e.g. of E6 and E7) is 
favored when E2 levels are low, and replication is favored when E2 levels are 
high. 
The placement of the E2BS within the viral genome also determines the 
functional outcome of E2 binding. High-affinity sites are distant from the ori and 
presumably activate transcription by promoting E2 multimerization, DNA 
looping, and recruitment of cellular transcription factors. Low-affinity sites are 
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close to the ori to recruit E1 and cellular replication factors (Ustav et al., 1993). 
Indeed, E1:E2 complex formation at these sites prevents nucleosome 
assembly (Li and Botchan, 1994) and binding of transcription factors such as 
TATA binding protein (TBP) (Hartley and Alexander, 2002). E2 occupies other 
E2BS in the minichromosome maintenance element (MME) within the URR 
during S phase and mitosis to mediate genome tethering to host chromosomes 
and ensure efficient partitioning to dividing host cells (Kadaja et al., 2009, 
Melanson and Androphy, 2009, Piirsoo et al., 1996). 
Mutation studies with different PVs suggest that individual amino acids 
in the E2 protein sequence contribute to each of its functions, since some 
mutants which cannot transactivate can still drive replication or vice versa 
(Grossel et al., 1996, Brokaw et al., 1996, Ferguson and Botchan, 1996, Abroi 
et al., 1996). Indeed, PVs have evolved to express multiple forms of E2 which 
separate these functions in a natural infection. Use of alternate start codons or 
splicing in the BPV-1 E2 open reading frame (ORF) yield gene products with 
masses of 31 kDa and 28 kDa (Hubbert et al., 1988). The former, referred to as 
E2C or E2R, spans aa 162-410 (Figure 1.4) and generally acts as a repressor 
of transcription (Lambert et al., 1990) and replication, though it may have more 
of a limit-setting function (e.g. establishing a set copy number in viral 
maintenance) since it still promotes these activites to some extent (Lim et al., 
1998, Lace et al., 2012). Such fine tuning of E2 activity occurs in part through 
dimerization: while heterodimers comprised of full-length E2 and E2R activate 
replication, E2R homodimers repress it (Lim et al., 1998). The 28 kDa protein, 
E8^E2, is the result of splicing from the E8 ORF to the C-terminus of the E2 
ORF (Figures 1.1 and 1.4), and it represses both replication and transcription 
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for HPV-16 (Straub et al., 2014). Controlled expression of E2R and E8^E2 may 
allow PVs to alternate between different E2 functions. 
Another means of E2 regulation, post-translational modification (PTM), 
may provide a more dynamic means of influencing E2 function since PTMs can 
be added and removed in less time than it takes to alter E2 gene transcription. 
Dynamic regulation is important for multifunctional proteins such as E2, 
especially since the actions of E2 directly affect the progression of the viral 
replicative cycle. The following chapters will discuss the role of different PTMs 
in E2 function and their implications for understanding PV biology. 
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FIGURE 1.4 
 
  
Figure 1.4. Structure of E2. (A) The E2 open reading frame (ORF) encodes 
multiple gene products through the use of alternate start codons and 
splicing. In BPV-1, the full-length E2 protein (amino acids/aa 1-410) has an 
N-terminal transactivating domain (N, green, aa 1-210), a flexible hinge 
region (yellow), and a C-terminal DNA-binding domain (C, purple, aa 286-
410). The truncated gene product E2R (aa 162-410), transcribed from an 
alternate start codon, lacks the majority of the TAD. E2R generally acts as 
a repressor, though weak transactivation has been detected in certain 
systems. The alternate splicing product E8^E2 combines 11 aa of E8 (black) 
with aa 206-410 of E2; this protein is a transcriptional repressor. Dotted 
lines, coding sequence not included in protein. (B) Full-length E2 binds 
E2BS (DNA, black bars) as a dimer. The DNA binding domains (left, blue 
and red circles; right, blue and red ribbons) interact to form an 8-stranded B 
barrel (right). Dimerization of the transactivating domains (gray ovals) is not 
necessary for E2 function. Dotted border, ribbon counterpart not shown 
(gray ribbon, TAD monomer). The BPV-1 E2 ribbon structure was generated 
in Protein Workshop (downloaded from rcsb.org/pdb) using the crystal 
structure 2JEU (Sanders et al., 2007), documented in the Papillomavirus 
Episteme (PaVE, pave.niaid.nih.gov) and the RCSB Protein Data Bank 
(PDB). 
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CHAPTER 2 
E2-MEDIATED TRANSCRIPTION AND ACETYLATION 
 
*Note: A portion of this work was published in Quinlan EJ, Culleton SP, Wu 
SY, Chiang CM, Androphy EJ.  2013.  Acetylation of conserved lysines in 
bovine papillomavirus E2 by p300.  J. Virol. 87 (3):1497-1507. 
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Introduction 
E2 Transcriptional Regulation 
 As mentioned in the previous chapter, the ability of papillomavirus E2 
protein to activate or repress transcription is linked in part to the location of its 
binding sites in viral DNA, expression of its truncated forms, and dimerization. 
BPV-1 E2 is particularly adept at activating transcription compared to other PVs 
because the BPV-1 URR contains the minichromosome maintenance element 
(MME), a region upstream of the P89 early promoter rich in E2BS (Figure 1.1). 
In addition to their roles in genome partitioning mentioned earlier, these E2BS 
are thought to act as transcriptional enhancers (Spalholz et al., 1987), allowing 
interaction between E2 binding the MME and E2 binding the early promoter by 
DNA looping (Knight et al., 1991). Conversely, E2BS within the promoters of 
HPVs such as HPV-11, 16, and 18 are arranged so that they overlap with the 
TATA box, preventing binding of cellular factors to viral DNA and formation of 
the transcription initiation complex (Dostatni et al., 1991, Demeret et al., 1997, 
Hartley and Alexander, 2002, Dong et al., 1994). These HPVs also lack the 
MME and only have four E2BS (Kurg, 2011). Indeed, in HPV-transformed cell 
lines, transfected BPV-1 E2 represses E6 and E7 expression: BPV-1 E2 
replaces the missing HPV E2 and binds to the E2BS to block transcription 
initiation (Goodwin et al., 1998, Wells et al., 2000). Above a certain level of E2 
protein, however, E2 dimers form in solution rather than on DNA, reducing 
transcription activation in a phenomenon known as squelching (Kovelman et 
al., 1996, Abroi et al., 1996). 
 
Cellular Co-factors for E2 Dependent Transcription 
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 The E2 TAD is essential for E2-dependent transcription (Haugen et al., 
1988) partly because it mediates interactions with cellular proteins. The 
truncated forms of E2 (E2R and E8^E2), which lack the TAD, can therefore act 
as transcriptional repressors (Lambert et al., 1987, Choe et al., 1989, Vande 
Pol and Howley, 1990). E2-interacting proteins include factors important for 
basal transcription, such as Sp1, TFIIB, and TFIID (Sandler et al., 1996, Yao et 
al., 1998, Rank and Lambert, 1995); factors involved in chromatin remodeling, 
such as Brd4 and Brm (Ilves et al., 2006, Kumar et al., 2007); and those which 
regulate cellular transcription through other mechanisms, such as Gps2 and 
Tax1BP1 (Breiding et al., 1997, Wang et al., 2009). The present work includes 
interaction studies with BPV-1 E2 and Brd4, Gps2, and Tax1BP1 as a cross-
section of E2 binding partners. 
 Brd4 is a member of the BET family of proteins, which each contain two 
bromodomains and a conserved extra-terminal (ET) domain (Wu and Chiang, 
2007). It is best known in cellular biology for binding the P-TEFb complex, which 
is required for transcriptional elongation (Vollmuth et al., 2009). Brd4 binds P-
TEFb with its extreme C-terminal domain (CTD, or motif, CTM) and interacts 
with acetylated lysines on histone tails via its bromodomains, thus providing a 
means for recruiting transcription elongation machinery onto so-called “open” 
chromatin (Filippakopoulos et al., 2012). In addition to its activities in uninfected 
cells, Brd4 has been implicated in several processes in PV biology. It was first 
found to interact with BPV-1 E2 via the CTD and mediate E2 tethering of viral 
genomes to mitotic chromosomes (You et al., 2004, Abbate et al., 2006) (Figure 
2.1). Studies utilizing the isolated CTD, which exerts a dominant negative effect 
on Brd4 when the two are co-expressed, revealed that PVs also require full-
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length Brd4 for transient replication and transcriptional activation (Ilves et al., 
2006, Schweiger et al., 2006). For HPVs, Brd4 can act as a chromatin insulator, 
preventing expression of E6 and E7 (Wu et al., 2006). In multiple PV types, 
mutation of the conserved residues arginine 37 (R37) and isoleucine 73 (I73) 
in the E2 TAD not only abrogate Brd4 binding but also inhibit transactivation, 
further highlighting the importance of Brd4 for PV transcription regulation 
(Senechal et al., 2007). Brd4 has also been shown to stabilize E2 by an as-yet-
unknown mechanism which requires direct interaction between the two proteins 
and prevents E2 proteasomal degradation (Lee and Chiang, 2009). 
Gps2 (AMF-1 in yeast), discovered as an E2 binding protein in a yeast 
two-hybrid screen (Breiding et al., 1997), directly bound and additively 
enhanced BPV-1 transactivation with the lysine acetyltransferase (KAT) p300 
(Peng et al., 2000). E2 interacts weakly with p300 by itself, but the interaction 
was strengthened in the presence of Gps2. This finding suggested that Gps2 
recruited E2 into a complex with p300, though the function of such a complex 
was still unknown (Peng et al., 2000). 
Tax1BP1 (named for its binding to human T-cell leukemia virus type 1 
(HLTV-1) protein Tax1; also abbreviated TXBP), is a partner in the ubiquitin 
editing complex with the deubiquitinase A20 and has roles in suppressing pro-
inflammatory NF-κB signaling and preventing apoptosis (Verstrepen et al., 
2011, Shembade et al., 2011). Tax1BP1 was found to bind BPV-1 E2, HPV-16 
E2, and HPV-18 E2; it not only stabilized these proteins in an E2-specific 
manner but also enhanced BPV-1 transcription activation in a p300-dependent 
manner (Wang et al., 2009). p300 was also found to bind Tax1BP1 directly. 
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FIGURE 2.1 
 
 
 
Figure 2.1. The E2:Brd4 interaction. Although Brd4 is over 1300 amino 
acids in length, only the last 20 have been found necessary to bind E2. The 
C-terminal domain (CTD, blue helix) binds perpendicular to the N-terminal α 
helices (green) of the E2 transactivating domain (TAD). This interaction has 
diverse outcomes depending on PV type and assay conditions, ranging from 
transcription activation to stabilization of E2 protein. Ribbon structures 
reprinted with permission from (Abbate et al., 2006). 
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Lysine Acetyltransferases and E2 Acetylation 
Despite the role of p300 in enhancing E2-mediated transcription from 
two separate protein complexes (E2:Gps2 and E2:Tax1BP1), acetylation of E2 
by p300 or any other KAT had not been observed. p300 is one of several KATs, 
also known as histone acetyltransferases (HATs) due to their initial discovery 
as post-translational modifiers of lysine residues in histone tails (Allfrey et al., 
1964). This function was first thought to loosen chromatin by decreasing the net 
positive charge on histones, but subsequent studies revealed a complex 
system with layers of specificity at the level of KATs, lysine residues, chromatin 
location, and tissue types (Hebbes et al., 1988, Kimura et al., 2005). Like p300 
and its close relative CREB-binding protein (CBP), several proteins known for 
their roles as transcription co-activators were found to possess 
acetyltransferase activity. These include two major families, GNAT (Gcn5-
related N-acetyltransferase) and MYST (MOZ, Ybf2/Sas3, Sas2, Tip60). The 
targets of these proteins are not limited to histones: the tumor suppressor p53 
is a notable target of p300, Tip60, and the GNAT family member PCAF, all of 
which act at different residues (Sakaguchi et al., 1998, Tang et al., 2006). 
Specific KAT:p53 interactions allow for fine-tuning of p53 function, such as 
favoring apoptosis versus cell-cycle arrest as in the case of Tip60 (Tang et al., 
2006). We expect that, if E2 were acetylated, it would be for the purpose of 
similar fine-tuning (e.g. favoring transcription over replication or vice versa). 
PVs both act on and depend on pathways in which KATs are involved. 
HPV-16 E6, for instance, targets the KAT complex component and p53 
transcriptional coactivator hAda3 for proteasomal degradation; this process 
depends on the ubiquitin ligase E6AP and prevents p14ARF-mediated 
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signaling to p300 for p53 acetylation and subsequent cell senescence (Kumar 
et al., 2002, Sekaric et al., 2007, Shamanin et al., 2008, Hu et al., 2009). CBP, 
p300, and PCAF have all been identified as binding partners and transcription 
co-activators for E2 from various PVs (Peng et al., 2000, Lee et al., 2000, Muller 
et al., 2002, Lee et al., 2002, Kruppel et al., 2008). Interestingly, both CBP and 
PCAF lacking intact KAT domains failed to support E2-mediated transactivation 
(Lee et al., 2002, Lee et al., 2000), suggesting that acetyltransferase activity is 
important for this function of KATs. However, the target of this activity in these 
studies was unknown. 
These findings led our lab to hypothesize that E2 acetylation is important 
for its transcription activation function. siRNA knockdown of three different 
KATs (p300, CBP, and PCAF) could not be functionally complemented by 
expression of the other two KATs, suggesting an independent mechanism for 
each in enhancing E2 transactivation (Quinlan et al., 2012). In vitro acetylation 
assays with p300 revealed several lysine acetylation sites on BPV-1 E2. Two 
of particular interest, K111 and K112 (Figure 2.2), were notable for their 
extremely high level of conservation among PVs, a previous report of their 
inclusion in a putative nuclear localization signal (NLS) (Skiadopoulos and 
McBride, 1996), and differential effects on transactivation of lysine to arginine 
(KR) point mutants at these sites (Brokaw et al., 1996). To determine whether 
acetylation at these sites might influence E2 transactivation, we mutated the 
residues to arginine. This mutation discourages acetylation while conserving 
side-chain size and charge. Although K111R and a double mutant, 
K111R/K112R, had less than 10% wild type transcriptional activity in a 
luciferase reporter assay, K112R stimulated transcription at about 70% of wild 
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type levels (Quinlan et al., 2012). These results were not only consistent with 
an earlier study (Brokaw et al., 1996) but also provided the first indication that 
E2 acetylation could regulate the protein’s activity. However, we sought to 
determine whether such modifications occurred in E2 expressed in cells. Here 
we show that both BPV-1 and HPV-31 E2 are acetylated at these sites in a live-
cell system. We also confirmed that BPV-1 K111R has a greater transactivation 
deficiency than K112R using a different cell line from our initial experiments. 
Furthermore, we initiated co-immunoprecipitation studies with KR mutants 
and Tax1BP1. These results support our hypothesis that E2 acetylation at these 
sites influences its ability to activate transcription, while suggesting future 
avenues for study to determine the mechanism of action. 
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FIGURE 2.2 
 
 
  
Figure 2.2. Lysines 111 and 112 in the BPV-1 E2 TAD. An in vitro 
acetylation assay with BPV-1 E2 and the acetyltransferase p300, followed 
by mass spectrometry, identified multiple acetylated lysines (K) including 
adjacent residues K111 and K112 (ball and stick model, inset: green, 
carbon; red, oxygen; blue; nitrogen). Gray ribbon, E2 TAD. The BPV-1 E2 
ribbon structure was generated as described in Figure 1.4. 
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Materials and Methods 
Cells and Transfections 
Cells used include C33a, an HPV-negative human cervical cancer cell 
line; C33a/E2, C33a cells stably expressing BPV-1 E2; and RPE1, an hTERT-
immortalized human retinal epithelial cell line. C33a and C33a/E2 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) 
supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals) and 1% 
penicillin-streptomycin solution (Pen-Strep, Invitrogen). RPE1 cells were 
cultured in a 1:1 mixture of DMEM and Ham’s F12 medium (Invitrogen) with 
10% FBS and 1% Pen-Strep. C33a/E2 cells were kind gifts of Dr. Peter Howley. 
Transfection of C33a cells was performed using the calcium phosphate method. 
C33a/E2 and RPE1 cells were transfected using Lipofectamine 2000 
(Invitrogen) at a 2:1 Lipofectamine:DNA ratio, with the DNA and transfection 
reagent diluted in Opti-MEM serum-free medium (Invitrogen). Media was 
replaced ~16 hours post-transfection for all experiments. 
 
    Mass Spectrometry 
Two BPV-1 samples were derived from either C33a/E2 cells or C33a 
cells transfected with pCG-BPV1 E2 (Table 1, Appendix). For the first sample, 
C33a/E2 cells were grown on 15-cm dishes and lysed in urea lysis buffer (8M 
urea, 100 mM Tris-HCl, pH 8, 100 mM NaCl, 0.1% NP-40) for one freeze-thaw 
cycle. Lysates were diluted in the same lysis buffer minus urea and incubated 
with Sepharose A and G beads cross-linked with two mouse monoclonal 
antibodies to BPV-1 E2, B201 and B202. Immunoprecipitants were resolved by 
SDS-PAGE and stained with InstantBlue Coomassie-based solution 
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(Expedeon). Two fragments from the 50-65 kDa region of the gel were excised 
and analysed separately. The second sample was derived from C33a cells 
grown on 10-cm dishes (Corning) transiently transfected with pCG-E2. Cells 
were lysed 48 hours post-transfection with NP-40 lysis buffer (0.5% NP-40, 50 
mM Tris-HCl, pH 8, 150 mM NaCl, 2mM Na3VO4, 10 mM NaF, protease inhibitor 
cocktail (Sigma)). Immunoprecipitation conditions were the same as those 
described above.  Immunoprecipitants were resolved, stained, and submitted 
to the Indiana University Proteomics Core Facility for analysis. 
HPV-31 samples were derived from C33a cells transfected with codon-
optimized Flag-tagged HPV-31 E2 plasmid (Table 1, Appendix). Cells were 
grown on 15-cm dishes and lysed in Flag lysis buffer (50 mM Tris HCl, pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1% Triton X-100; from the Sigma M2 Affinity Gel 
Technical Bulletin, Cat. # A2220). Tagged protein was immunoprecipitated with 
M2 Affinity Gel and resolved, stained, and submitted for analysis as described 
above. 
The gel bands for mass spectrometric analysis were first reduced with 
10 mM DTT in 10 mM ammonium bicarbonate and then alkylated with 55 mM 
iodoacetamide (prepared freshly in 10 mM ammonium bicarbonate). Alkylated 
samples were digested by trypsin (Promega) overnight at 37°C. Tryptic 
peptides were injected onto a C18 trapping column (NanoAcquity UPLC® Trap 
column 180μm x 20mm, 5μm, Symmetry C18) first before an analytical column 
(NanoAcquity UPLC® column 100μm x 100mm, 1.7μm BEH130 C18). Peptides 
were eluted with a linear gradient from 3 to 40% acetonitrile in water with 0.1% 
formic acid developed over 90 min at room temperature at a flow rate of 500 
nL/min, and the effluent was electro-sprayed into a Thermo-Fisher Scientific 
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LTQ Orbitrap Velos Pro mass spectrometer (Thermo-Fisher Scientific) 
interfaced with a Waters Acquity® UPLC system (Waters). Analysis of 
phosphopeptides was performed using a data dependent neutral loss scan. 
Blanks were run prior to the sample run to make sure there were no significant 
background signals from solvents or the columns. Database search and data 
analysis were performed using the Thermo-Fisher Scientific Proteome 
DiscovererTM software (v1.3). 
 
    Luciferase Reporter Assays 
C33a cells were grown in 12-well dishes (BD Falcon). Transfections 
were performed in triplicate. 48 hours post-transfection, cells were rinsed with 
DPBS and lysed with Steady-Glo. Lysates were transferred to 96-well Opti-
Plates (PerkinElmer) and luminescence was measured with the Pherastar 
system. A monomeric RFP-GFP (mRFP-GFP) control was used to measure 
transfection efficiency. 
 
    Western Blot and Co-Immunoprecipitation  
 For co-immunoprecipitation (co-IP), C33a cells were transfected with 
BPV-1 E2 wild type or mutant encoding plasmids and 3x-Flag tagged Tax1BP1 
(Table 1, Appendix). 48 hours post-transfection, cells were lysed and 
immunoprecipitated with B201 as described in (Wang et al., 2009). IP samples 
and inputs were resolved by SDS-PAGE and transferred onto PVDF 
membranes (Millipore), and proteins were detected by B201, M2 anti-Flag 
(Sigma), and anti-mouse HRP secondary antibody (Jackson Labs). Blots were 
developed with SuperSignal West Dura (Thermo Pierce) and were imaged 
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using ImageQuant LAS 4000 imager and software (GE Healthcare). 
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Results 
E2 lysines are acetylated in cells 
 After having discovered the in vitro acetylation events in BPV-1 E2, we 
sought to determine whether this modification occurred on the protein in live 
cells. Two separate BPV-1 E2 protein samples were purified either from 
transfected C33a cells, an HPV-negative human cervical cancer cell line in 
which E2 transcription and replication activities are commonly tested, or 
C33a/E2 cells, a C33a-derived cell line stably expressing E2 at near-
physiologic levels (You et al., 2004). Flag-tagged HPV-31 E2 protein was 
purified from transfected C33a cells. Protein samples were submitted to the 
Indiana University Proteomics Core for linear ion trap mass spectrometry. 
Spectra analysis by the Core revealed acetylation on K112 of BPV-1 E2 and 
K111 of HPV-31 E2 (Tables 2 and 3, Appendix). These results validated the in 
vitro acetyltransferase assay for BPV-1 E2, since acetylation was detected at 
other residues noted in vitro including K25, K70, K107, K226, K339, K346, and 
K347 (Quinlan et al., 2012). 
 
E2 lysine mutants differentially influence transcription 
 Since K111 and K112 are conserved across almost all PVs, these 
residues were selected for functional analysis. We used lysine to arginine 
(KR) mutants from our previous work (Quinlan et al., 2012): K111R, K112R, 
and the double mutant K111R/K112R. Transactivation assays using the pGL2-
E2BS-Luc firefly luciferase reporter (Table 1, Appendix) were conducted initially 
in RPE1 cells, a highly transfectable human retinal epithelial cell line 
immortalized with hTERT. These assays suggested that K111R and the double 
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mutant, but not K112R, were deficient for transcription activation (Quinlan et 
al., 2012). We sought to confirm those findings in a different cell line, choosing 
C33a cells for their comparable transfectability and closer approximation to 
natural PV host cells. Again, using the E2BS-Luc reporter, which contains four 
E2BS upstream of an SV-40 promoter (Kumar et al., 2007), we found that 
K112R transactivation function was mostly intact, while both K111R and the 
double mutant diminished transactivation to less than 10% wild type levels 
(Figure 2.3) (Quinlan et al., 2012). Readouts were normalized to cells 
transfected with monomeric RFP-GFP (mRFP-GFP) plus empty vector for 
transfection efficiency detection by fluorescence (Table 1, Appendix). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
FIGURE 2.3 
 
 
 
 
Figure 2.3. Lysine mutants differentially activate transcription. C33a 
cells were grown in 12-well dishes. Samples were transfected in triplicate 
wells with 50 ng/well pCG-E2 wild type or mutants (WT, K111R, K112R, 
K111R/K112R), as well as 75 ng/well pGL2-E2BS-Luc. 48 hours post-
transfection, cells were lysed on-plate with 100 μl Steady Glo reagent. 
Lysates were mixed with 100 μl DPBS and transferred to a white 96-well 
plate for luminescence detection using the Pherastar system. 
Luminescence for each sample was divided by WT luminescence to get fold 
WT activation, and Student’s t test was used to compare each sample to 
WT. ****, p<0.00001. Values are expressed as mean +/- SEM. 
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    E2 lysine mutants differentially affect protein expression and 
interaction with a transcription co-activator 
 The mutants K111R, K112R, and K111R/K112R were previously 
demonstrated to be expressed at different levels, with K112R closest to wild 
type, followed by K111R with less than 50% wild type expression and the 
double mutant with less than 20% (Quinlan et al., 2012). In addition to protein 
expression, we wanted to assess the mutants’ capacity to bind a known E2 
transcriptional co-activator, Tax1BP1. C33a cells were transfected with BPV-1 
E2 wild type or mutant and 3x-Flag Tax1BP1, and lysates were 
immunoprecipitated with B201, a mouse monoclonal antibody against an 
epitope between aa 160 and 220 of BPV-1 E2 (Wang et al., 2009). Western 
blotting revealed that, despite comparable levels of E2 wild type and mutant 
immunoprecipitation, Tax1BP1 co-IP varied drastically. Wild type and K112R 
pulled down the highest levels of Tax1BP1, while all other mutants showed 
substantially decreased association with the cellular protein (Figure 2.4). 
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FIGURE 2.4 
 
 
 
 
Figure 2.4. Lysine mutants differentially associate with Tax1BP1. C33a 
cells were grown on 6-cm dishes and transfected with 1 μg each mRFP-
GFP (-), BPV-1 E2 wild type and the K111R, K112R, and double mutants 
(WT, 1R, 2R, 1R/2R), and 3x-Flag Tax1BP1 (TXBP). Cells were harvested 
48 hours post-transfection. 10% of each lysate was set aside for input, while 
remaining lysate was incubated with protein sepharose A and G beads and 
the anti-BPV-1 E2 mouse monoclonal antibody B201 at 4°C overnight. 
Western blots were probed for 3x-Flag TXBP and BPV-1 E2 using the 
mouse monoclonal anti-Flag antibody M2 and B201, respectively. *, 
nonspecific band. 
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Discussion and Future Directions 
 As small viruses encoding less than a dozen genes, the 
papillomaviruses are dependent on cellular machinery for assistance in 
carrying out essential functions. While the E2 protein has been shown to bind 
numerous cellular proteins, and many of these interactions are important for 
viral transcription, replication, and other activities, the exact mechanisms 
remain unclear (Smith et al., 2010, Muller and Demeret, 2012, Muller et al., 
2012). 
 Previous work in our laboratory revealed multiple acetylation sites in 
BPV-1 E2 in vitro and demonstrated the importance of three different KATs – 
p300, CBP, and PCAF – in supporting E2-mediated transcription activation. 
This work showed that two KR mutants, K111R and K112R, differentially 
affected E2 transactivation and protein expression, as well as DNA binding and 
subcellular localization (Quinlan et al., 2012). These results confirmed previous 
reports describing the effects of K111 and K112 on transcription (Brokaw et al., 
1996) as well as their inclusion in a putative nuclear localization signal (NLS) in 
the E2 TAD (Skiadopoulos and McBride, 1996). 
 In the present study, mass spectrometry analysis of E2 harvested from 
cells confirmed K112 acetylation for BPV-1 E2 and K111 acetylation for the 
previously untested HPV-31 E2 protein. The absence of the other PTM (i.e. Ac-
K111 for BPV-1 and Ac-K112 for HPV-31) should not be used to rule them out 
as possibilities; rather, the results may reflect a snapshot of conditions in these 
cell populations, or may even reflect differences in the cells themselves or the 
surface exposure of these residues in vivo. It is also possible that PTMs besides 
acetylation occur at these lysines. The use of a single residue for multiple types 
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of PTM has already been documented for other proteins such as p53, which 
has several lysines that serve as substrates for acetylation, ubiquitination, 
sumoylation, and neddylation (Tang et al., 2006, Kim et al., 2011, Liu et al., 
2014, Bischof et al., 2006, Guihard et al., 2012). 
 Luciferase reporter assays in C33a cells confirmed previous findings in 
RPE1 cells that K111R and K111R/K112R were almost completely defective 
for transcription activation and K112R was mildly defective (Quinlan et al., 
2012). While conformational changes resulting from the mutations themselves 
cannot be ruled out, transcription impairment may be due in part to reduced 
protein levels for K111R and the double mutant compared to K112R or wild 
type (Quinlan et al., 2012). Transiently transfected E2 drives its own 
transcription, so transactivation-defective mutants are unable to elevate their 
own protein levels. However, repeating this assay with titrations of the mutants 
to several-fold higher transfection amounts did not rescue their function 
(Quinlan et al., 2012). Despite comparable levels of immunoprecipitation for 
wild type, K111R, and K112R, co-IP of Tax1BP1 varied widely (Figure 2.4). 
Again, the mutation itself or the lack of acetylation at these sites may induce a 
conformational change preventing interaction. Interestingly, looking at the 
Tax1BP1 input levels for this experiment, both wild type and K112R but not 
K111R seemed to stabilize Tax1BP1. This suggests that intact K111, or 
acetylation at K111, is important for this ability of E2, or that acetylation at K112 
would actually destabilize Tax1BP1. It is difficult to draw conclusions from the 
double mutant since its expression was low, possibly confounding the co-IP 
results. Even though diminished interaction with Tax1BP1 may not be the only 
mechanism responsible for impaired K111R transactivation, the co-IP results 
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point to altered transcription co-factor binding as a general means of regulation 
at this site. Thus far, our results suggest that: (1) acetylation at K111 is 
important for transactivation since the mutant was defective for this function in 
the luciferase assay; (2) acetylation at K111 may stabilize Tax1BP1, or K112 
acetylation may lead to its destabilization (since K111R and K112R were 
associated with lower and higher levels of TaxBP1 relative to baseline, 
respectively); and (3) Tax1BP1 can bind all of the mutants, but this interaction 
is apparently not sufficient for E2 transactivation. 
 Studies to further elucidate the role of K111 and K112 in PV biology are 
currently under way in our laboratory. These sites are now being examined in 
the context of HPV-31 E2, since this PV is more relevant to human disease and 
was found to be acetylated at K111 in cells. Co-IP studies with Brd4 and Gps2 
are also in progress. We expect the results to be similar to those for the BPV-1 
E2:Tax1BP1 interaction, supporting the hypothesis that K111 acetylation 
inhibits co-factor association generally. If just the Gps2 results follow a similar 
pattern to Tax1BP1, this would suggest the importance of E2 acetylation by 
p300 in enhancing Gps2- and Tax1BP1-dependent E2 transcription. Brd4 
contains bromodomains, which recognize acetylated lysines; although Brd4 
has previously been observed to bind E2 through its CTD (Abbate et al., 2006), 
this does not preclude the use of other interaction sites. Tax1BP1 co-IP should 
also be repeated in the HPV-31 system to determine whether different viruses 
use similar PTMs at conserved residues. 
 We can refine our earlier hypothesis that post-translational modification 
(PTM) of E2 is one means of controlling the timing and magnitude of various 
E2 functions: we also assert that this is accomplished by altering the viral 
38 
protein’s association with cellular factors. We propose that K111 acetylation of 
E2 occurs late in BPV-1 infection to promote E2 transactivation. This would 
coincide with elevated p300 expression, which is found in differentiating cells 
(Wong et al., 2010). Additional experiments of interest include transcription 
assays with wild type versus KAT-deficient p300 to determine whether 
acetylation – not just an intact lysine residue – is necessary for transactivation. 
We would also like to harvest HPV-31 positive cells (such as CIN612 or 
transfected HaCaT) in different cell-cycle stages or maturation states (i.e. 
proliferating versus differentiated keratinocytes) for comparison of HPV-31 E2 
PTMs by mass spectrometry. Although we reported the first known acetylation 
events in both BPV-1 E2 and HPV-31 E2, their role in the PV replicative cycle 
remains to be seen. The suggested experiments would provide further insight 
into the significance of these PTMs in natural infection. 
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CHAPTER 3 
TYROSINE PHOSPHORYLATION IN BPV-1 E2 
 
*Note: A portion of this work has been submitted for publication and is 
currently under revision. 
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Introduction 
Papillomavirus Proteins and Phosphorylation 
The first PTMs detected on papillomavirus E2 proteins were serine 
phosphorylation events in the BPV-1 E2 hinge. These included serines 290, 
298, and 301 (McBride et al., 1989). An “A3” mutant of the protein, with all three 
serines changed to alanines, stimulated replication to levels 20-fold higher than 
wild type in C127 cells, a murine fibroblast cell line (McBride and Howley, 1991). 
Increased stability of the mutant E2 protein likely contributed to this increase in 
replication activity; an S301A mutant was found to have a longer half-life and 
reduced ubiquitination compared to wild type (Penrose and McBride, 2000). 
Additionally, S301 phosphorylation induced a conformational change that 
destabilizes E2 (Penrose et al., 2004). Casein kinase II (CKII or CK2) 
phosphorylates S301 (Penrose et al., 2004). The enzyme recognizes this 
residue in the context of a PEST sequence, a stretch of amino acids rich in 
proline (P), glutamate (E), serine (S), and threonine (T) that is common to 
rapidly degraded proteins (Rogers et al., 1986). 
Unlike the original three phospho-serines, an additional phosphorylation 
event at S235 appeared to enhance E2 activity since it was required for stable 
replication of viral genomes and tumorigenic transformation in C127 cells 
(Lehman et al., 1997). Indeed, an “A4” mutant – A3 plus S235A – failed to tether 
viral DNA to mitotic chromosomes (Lehman and Botchan, 1998). The kinase 
responsible for this phosphorylation event is unknown. Phosphorylation sites 
reported in other PVs include S253 in HPV-8 E2 mediated by protein kinase A 
(PKA) and S243 in HPV-16 E2; the presence of the PTM at both sites allows 
E2 to bind host chromatin (Sekhar and McBride, 2012, Chang et al., 2014). 
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Studies in HPV-16 suggest that these sites are dephosphorylated upon 
differentiation, though this may not apply to all PVs. The phosphatase 
calcineurin dephosphorylates HPV-16 E2: a scaffold protein, NRIP, brings E2 
in contact with calmodulin (CaM), which recruits calcineurin (Chang et al., 2011, 
Kahl and Means, 2003). This leads to decreased ubiquitination and subsequent 
stabilization of E2. NRIP is known to bind CaM when calcium levels are high, 
and incubation in high-calcium media is known to differentiate keratinocytes. 
Since E2-dependent genome replication is highest in differentiated cells, it is 
expected that release of E2 from an inhibitory modification would be linked to 
changes in intracellular calcium by the NRIP/CaM/calcineurin complex. 
Upon differentiation, E1 is cleaved by caspases 3 and 7 (Moody et al., 
2007, Morin et al., 2011), and its exclusion from the nucleus is relieved by 
phosphorylation of its nuclear export signal (NES) (Sakakibara et al., 2013); the 
cleaved E1 is then imported to the nucleus to initiate replication along with E2 
in a DDR-dependent manner (McBride et al., 2012). 
E2 is not the only viral protein which undergoes serine phosphorylation. 
CK2 acts on the viral helicase E1 as well as E2, decreasing both proteins’ DNA 
binding specificity and minimizing replication during viral maintenance (Schuck 
et al., 2013). Upon host-cell differentiation, the phosphorylation on E1 is lost via 
caspase-dependent cleavage, allowing full activity of the protein. In HPV-31 E1, 
phosphorylation at S92 and S106 by cyclin-dependent kinase 2 (Cdk2) 
activates a nuclear export signal (NES) in the protein, relocating it to the 
cytoplasm (Fradet-Turcotte et al., 2010a). Since E1 export is required for viral 
genome maintenance and nuclear buildup of the protein is harmful to cells, 
these two sites are thought to be dephosphorylated upon terminal host-cell 
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differentiation, when maximal E1 activity is needed and host-cell lethality is no 
longer an issue. 
 
Tyrosine Kinases and Papillomavirus Infection 
 Although no tyrosine or threonine phosphorylation events have been 
reported to date for any PV protein, various tyrosine kinases (TKs) are targets 
of PV oncoproteins. The E5 protein of BPV-1 is a small (44 aa) oncogene 
product which is required for cellular transformation (Schlegel et al., 1986, 
DiMaio et al., 1986, Schiller et al., 1986, Horwitz et al., 1988). Though it carries 
out its transforming function by activating cellular platelet-derived growth factor 
β receptor (PDGF-R) (Lai et al., 1998, Klein et al., 1999, DiMaio et al., 2000), 
E5 can also induce transformation by promoting constitutive activation of c-Src, 
a non-receptor TK (Suprynowicz et al., 2002). c-Src activation was mediated by 
E5 mutants defective for PDGF-R binding, indicating that E5 can transform cells 
by two independent mechanisms. The E6 and E7 oncoproteins also promote 
increased TK activity. HPV-16 E7 was shown to activate c-Src family members 
Fyn, Src, and Yes in keratinocytes by promoting increased protein expression 
and autophosphorylation (Szalmas et al., 2013). E6 from the same virus 
maintained signaling from the receptor tyrosine kinases (RTKs) epidermal 
growth factor receptor (EGFR) and insulin-like growth factor receptor (IGF-1R) 
independent of the receptors’ ligands by promoting their internalization 
(Spangle and Munger, 2013). E6 also assists TKs by inhibiting proteins that 
counter their activity: both HPV-16 and HPV-18 E6 were found to target protein 
tyrosine phosphatase H1 for proteasomal degradation (Topffer et al., 2007). 
 Because PV oncoproteins promote TK activity, we hypothesized that a 
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TK itself might be involved in a regulatory feedback loop and act on one or more 
viral proteins. The E2 protein would be a reasonable target since it has the 
ability to repress viral oncoprotein expression (Wells et al., 2000, Prabhavathy 
et al., 2015). TK activation may promote transcription repression by E2, or it 
may be a counter-strategy employed by PV oncoproteins to neutralize E2 and 
promote conditions conducive to viral DNA integration, loss of E2 expression, 
and oncogenic transformation. 
 In our search for E2 acetylation events in cells described in the previous 
chapter, we found several other PTMs, including tyrosine phosphorylation. 
Since no tyrosine phosphorylation event had ever been reported for E2, we 
sought to investigate the potential significance of this PTM. We show that BPV-
1 E2 is phosphorylated at tyrosine 102 (Y102), and that point mutants at this 
site which prevent or mimic phosphorylation have differential effects on E2-
mediated transcription, replication, and binding to cellular co-factors. We also 
demonstrate the first evidence of direct binding of BPV-1 E2 to multiple receptor 
tyrosine kinases and assert that one or more of these RTKs acts on E2 to 
modulate its function in the early stages of the viral replicative cycle. 
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Materials and Methods 
Cells and Transfections 
C33a, C33a/E2, HEK293TT, CV-1, A3, and ID13 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 
10% fetal bovine serum (Atlas Biologicals) and 1% penicillin-streptomycin 
solution (Pen-Strep, Invitrogen). HaCaT cells were cultured in low-calcium (0.1 
mM) DMEM with Pen-Strep.  C33a/E2 cells were a kind gift of Drs. Peter 
Howley and Jianxin You. C33a cells were transfected either by the calcium 
phosphate method (mass spectrometry and transactivation assays) or by 
Lipofectamine 2000 (Invitrogen) at a 1:1 Lipofectamine:DNA ratio (replication 
assays). HEK293TT cells were transfected using the calcium phosphate 
method. CV-1 cells were transfected using Lipofectamine 2000 at a 2:1 
Lipofectamine:DNA ratio. For transfections with Lipofectamine 2000, the DNA 
and transfection reagent were diluted in Opti-MEM serum-free medium 
(Invitrogen). Media was replaced ~16 hours post-transfection for all 
experiments. 
 
    Plasmids and Mutagenesis 
Expression plasmids used include pCI, pEGFP-C1, mRFP-GFP, pCG-
E2 for full-length wild-type (WT) BPV-1 E2, pCG-E2R for the truncated form of 
BPV-1 E2, pCG-E1 for BPV-1 E1, pHA:AMF1 for HA-tagged Gps2/AMF1, and 
p3XFLAG-CMV-7.1 Tax1BP1 for Tax1BP1. Tyr-Phe (Y102F) and Tyr-Glu 
(Y102E) mutations in BPV-1 E2 were generated using the QuikChange II site-
directed mutagenesis system according to the manufacturer’s instructions 
(Agilent Technologies). Briefly, pCG-BPV1E2 was used as a template for the 
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reaction. After the presence of a PCR product was confirmed by DNA gel 
electrophoresis, DH5α E. coli cells were transformed by heat shock, recovered, 
and spread onto LB-Ampicillin plates to grow overnight at 37°C. Colonies were 
selected the following day for DNA isolation, and mutation was confirmed by 
sequencing. Primers used for the mutagenesis reaction include 5’-
CACAAGCTGGGACCGATTCATGTCAGAACCTAAAC-3’ (forward) and 5’-
GTTTAGGTTCTGACATGAATCGGTCCCAGCTTGTG-3’ (reverse) for Y102F 
and 5’-CACAAGCTGGGACCGAGAGATGTCAGAACCTAAACG-3’ (forward) 
and 5’-CGTTTAGGTTCTGACATCTCTCGGTCCCAGCTTGTG-3’ (reverse) for 
Y102E. pVL-F:hBrd4 for full-length Flag-tagged Brd4, pGEX:hBrd4(1224-1362) 
for GST-CTM, and pGEX:hBrd4(524-579) for GST-BID were kind gifts of Dr. 
Cheng-Ming Chiang. Luciferase reporter constructs included pGL2-E2BS-Luc 
for transactivation assays and pFLORI-BPV1 (firefly luciferase with long BPV-
1 ori) as well as pRL (Renilla) for replication assays. The latter two plasmids 
were generously provided by Dr. Jacques Archambault, along with pCG-BPV-
1 E1 Eag1235 (BPV-1 E1 with enhanced activity) for the E2-FGFR3 replication 
assays (see below). Dr. Leslie Thompson generously shared plasmids 
encoding wild-type human FGFR2, Flag-FGFR3, and FGFR4 (pRK7-FGFR2, 
pRK7-FGFR3-Flag, and pRK7-FGFR4) as well as the constitutively active Flag-
tagged FGFR3 mutant K650E (pRK7-FGFR3KE-Flag). The pcDNA3-EphB2 
construct encoding chicken EphB2 was a kind gift of Dr. Elena Pasquale. See 
also Table 1 in the Appendix. 
 
    Mass Spectrometry 
 Two separate BPV-1 E2 samples were analyzed by mass spectrometry. 
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One sample was derived from C33a/E2 cells, a cell line generated in the 
Howley lab that stably expresses BPV-1 E2. Cells were grown on 15-cm dishes 
(Corning), released from plates with 0.05% trypsin solution (Invitrogen), 
pelleted, and then frozen at -80°C. A total of 15 frozen pellets were thawed, 
lysed in urea lysis buffer (8M urea, 100 mM Tris-HCl, pH 8, 100 mM NaCl, 0.1% 
NP-40), pooled, and diluted in buffer minus urea for immunoprecipitation with 
equal volumes Sepharose A and G beads (Invitrogen) cross-linked with two 
mouse monoclonal antibodies to BPV-1 E2, B201 and B202 (B201/2 A/G 
beads). After 4 hours of rotation at 4°C, beads were washed 5 times with TBS, 
alternating between low and high salt (150 mM and 500 mM). Beads were then 
suspended in Laemmli SDS-PAGE sample buffer plus 5% β-mercaptoethanol 
(BME) (Fisher), heated at 95°C, and run on a 12.5% SDS-PAGE mini gel. After 
staining with InstantBlue Coomassie-based solution (Expedeon), a region 
spanning 50-65 kDa was excised and divided into 4 fragments to be analyzed 
separately. 
Additional samples were derived from C33a cells transfected with pCG-
E2 and cultured on four 10-cm dishes. Cells were lysed 48 hours post-
transfection with NP-40 lysis buffer (0.5% NP-40, 50 mM Tris-HCl, pH 8, 150 
mM NaCl, 2mM Na3VO4, 10 mM NaF, protease inhibitor cocktail (Sigma)). 
B201/2 A/G beads were used to immunoprecipitate E2. After low/high salt TBS 
washes as described above, beads were suspended in Laemmli buffer plus 
BME, boiled, and loaded on a 10% SDS-PAGE gel. After InstantBlue staining, 
bands spanning 45-50 kDa were excised. 
The gel bands for mass spectrometric analysis were first reduced with 
10 mM DTT in 10 mM ammonium bicarbonate and then alkylated with 55 mM 
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iodoacetamide (prepared freshly in 10 mM ammonium bicarbonate). Alkylated 
samples were digested by trypsin (Promega) overnight at 37°C. Tryptic 
peptides were injected onto a C18 trapping column (NanoAcquity UPLC® Trap 
column 180μm x 20mm, 5μm, Symmetry C18) first before an analytical column 
(NanoAcquity UPLC® column 100μm x 100mm, 1.7μm BEH130 C18). Peptides 
were eluted with a linear gradient from 3 to 40% acetonitrile in water with 0.1% 
formic acid developed over 90 min at room temperature at a flow rate of 500 
nL/min, and the effluent was electro-sprayed into a Thermo-Fisher Scientific 
LTQ Orbitrap Velos Pro mass spectrometer (Thermo-Fisher Scientific) 
interfaced with a Waters Acquity® UPLC system (Waters). Analysis of 
phosphopeptides was performed using a data dependent neutral loss scan. 
Blanks were run prior to the sample run to make sure there were no significant 
background signals from solvents or the columns. Database search and data 
analysis were performed using the Thermo-Fisher Scientific Proteome 
DiscovererTM software (v1.3). 
 
    Luciferase Reporter Assays 
For transcriptional assays, C33a and CV-1 cells were cultured in 12-well 
dishes (BD Falcon). Transfections were performed in triplicate. 48 hours post-
transfection, cells were rinsed with DPBS (Invitrogen) and lysed with Steady-
Glo luciferase substrate (Promega). Lysates were transferred to 96-well Opti-
Plates (PerkinElmer) and luminescence was measured with a Pherastar plate 
reader and software. Transient replication assays were performed using C33a 
cells on 96-well white-walled, clear-bottom plates (Corning). 72 hours post-
transfection, cells were lysed and treated with the Dual-Glo luciferase system 
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(Promega). Firefly and Renilla luminescence were measured using the 
Pherastar system. 
Statistical Analysis. All experiments were repeated at least 3 times. Student’s 
t test was performed for luciferase assays comparing wild type to mutant 
function. For all experiments, means are expressed +/- SEM.  p-values ≤ 0.05 
were considered significant. 
 
    Immunoprecipitation and Immunoblotting 
Unless otherwise indicated, HEK293TT cells were used for these 
experiments, were grown on 6-cm dishes (Corning), and were harvested for 
experiments 48 hours post-transfection. All cells were rinsed with cold DPBS 
before lysis with buffers described below. Lysis occurred for 30 minutes on ice, 
followed by centrifugation at 4°C at 12,000 rpm for 10 minutes. For 
immunoprecipitation (IP) experiments, total supernatant from each sample was 
used after setting aside 5-10% for input; for non-IP immunoblots, volumes 
corresponding to equal protein were measured as determined by BCA assay 
(Pierce Thermo Scientific). Samples were suspended in Laemmli buffer plus 
BME, boiled, run on SDS-PAGE gels, and transferred onto 0.45 μm PVDF 
membranes (Millipore) in semi-dry transfer boxes (Bio-Rad). Membranes were 
blocked in 5% milk, incubated overnight at 4°C with appropriate primary 
antibodies (below), washed with PBST, and incubated at room temperature with 
either goat anti-mouse or goat anti-rabbit light chain specific antibodies 
conjugated to horseradish peroxidase (Jackson Labs). Signals were detected 
with SuperSignal West Dura ECL solution (Pierce) and Amersham ECL Prime 
(GE Healthcare) using the ImageQuant LAS 4000 system (GE Healthcare). All 
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experiments were repeated at least 3 times. 
Lysis, wash, and primary antibody specifications are as follows: 
BPV-1 E2 wild-type and mutant immunoblot. HEK293TT, C33a, or CV-1 cells 
were lysed in NP-40 lysis buffer (see Mass Spectrometry, above) and subjected 
to BCA assay (Pierce Thermo Scientific) after ice incubation and centrifugation. 
Volumes corresponding to 40 μg were measured, brought to equal volume with 
lysis buffer, and mixed with Laemmli buffer plus BME prior to western blotting. 
Blots were probed with B201. 
E2:Flag-Brd4 and E2:E1 IPs. Cells were lysed in NP-40 lysis buffer (see Mass 
Spectrometry, above) and treated with Benzonase nuclease (Millipore) for 1 
hour before centrifugation. Protein complexes were immunoprecipitated with 
M2 anti-Flag conjugated agarose beads (M2 Affinity Gel, Sigma) or B201/2 A/G 
beads (see Mass Spectrometry, above). Beads were washed 5 times 
alternating 150 mM and 500 mM TBS. Blots were probed with B201 and either 
M2 antibody (Sigma) or 502-2 (rabbit polyclonal against BPV-1 E1). 
E2:HA-Gps2 IP. Cells were lysed in DPBS (Invitrogen) plus 0.5% NP-40 and 
protease inhibitors and immunoprecipitated with 1:1 Sepharose A and G bead 
slurry plus II-I (rabbit polyclonal against BPV1 E2). Beads were washed 3 times 
with NETN buffer. Blots were probed with B201 and HA-7 (Sigma). 
E2:3xFlag-Tax1BP1 IP. Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 8, 
100 mM NaCl, 20 mM NaF, 50 mM KH2PO4, 1% Triton X-100, 10% glycerol, 2 
mM dithiothreitol (DTT), and protease inhibitor cocktail). After centrifugation, 
lysates were mixed with equal volumes of binding buffer (50 mM Tris-HCl, pH 
8, 100 mM KCl, 0.1 mM EDTA, 0.2% NP-40, 0.1% bovine serum albumin, 2.5% 
glycerol, 2 mM DTT, and protease inhibitor cocktail) and immunoprecipitated 
50 
with 1:1 sepharose A/G bead slurry plus II-I. Beads were washed 5 times with 
low- or high-salt wash buffer (100 mM Tris-HCl, pH 8, 100 to 300 mM NaCl, 
0.5% NP-40, and 2 mM DTT). Blots were probed with M2 and B201. 
E2:GST-CTM and E2:GST-BID IPs. Cells were lysed in high-salt lysis buffer 
(50 mM Tris-HCl, pH 8, 400 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 
protease inhibitor cocktail). For IP, equal volume of no-salt lysis buffer was 
added, as well as glutathione Sepharose beads (GE Healthcare) and ethidium 
bromide to 0.1 μg/μl. Beads were washed 3 times with binding buffer (50 mM 
Tris-HCl, pH 8, 100 mM KCl, 0.1 mM EDTA, 0.2% NP-40, 0.1% BSA, 2.5% 
glycerol). Blots were probed with B201 and SD8 (rabbit polyclonal against 
GST). 
E2:FGFR IPs. Cells were lysed in 1% NP-40 lysis buffer (1% NP-40, 50 mM 
Tris-HCl, pH 8, 150 mM NaCl, protease inhibitor cocktail) and 
immunoprecipitated with 1:1 Sepharose A/G bead slurry plus II-I. Beads were 
washed 3 times with lysis buffer. Blots were probed with B201 and M2, Bek 
antibody C-17 (rabbit anti-FGFR2, Santa Cruz Biotechnologies), FGFR4 
antibody C-16 (rabbit, Santa Cruz). 
Other E2:kinase IPs. Cells were lysed in IGF-1R lysis buffer (300 μM NaCl, 
0.5% NP-40, 20 mM Tris-HCl, pH 8, 1 mM EDTA, protease inhibitor cocktail) 
and immunoprecipitated with 1:1 Sepharose A/G bead slurry plus II-I. Beads 
were washed 3 times with lysis buffer. Blots were probed with B201 and 
antibodies against EphB2 (mouse anti-EphB2 AM11064PU-N, Acris 
Antibodies), Met C-28 (rabbit anti-c-Met sc-161, Santa Cruz), and IGF-1Rβ C-
20 (rabbit anti-IGF-1R sc-713, Santa Cruz). 
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    Immunofluorescence 
CV-1 cells were grown on 12-well plates (BD Falcon) with 18-mm glass 
coverslips. 48 hours post-transfection, cells were rinsed with cold DPBS and 
fixed in 4% paraformaldehyde solution for 15 minutes. After permeabilization in 
antibody dilution buffer (5% normal goat serum and 0.1% Triton X-100 in 
DPBS), cells were incubated in dilution buffer plus B201 supernatant at 4°C 
overnight. Coverslips were incubated in dilution buffer plus AlexaFluor 594 anti-
mouse secondary antibody (Invitrogen) and mounted onto slides with ProLong 
Gold plus DAPI (Invitrogen). Slides were imaged with a Zeiss fluorescent 
microscope using QCapture Pro 6 software. 
 
    Software and Web Resources 
 The BPV-1 E2 ribbon structure was generated in Protein Workshop 
(downloaded from rcsb.org/pdb) using the crystal structure 2JEU (Sanders et 
al., 2007), documented in the Papillomavirus Episteme (PaVE, 
pave.niaid.nih.gov) and the RCSB Protein Data Bank (PDB). PaVE was also 
used to obtain information for Tables 4 and 5 in the Appendix. The full-length 
BPV-1 E2 amino acid sequence was obtained from PaVE for use as input in 
phosphorylation site predictive software, including GPS 2.1 (downloaded from 
gps.biocuckoo.org), NetPhos 2.0 (www.cbs.dtu.dk/services/NetPhos/), and 
ScanSite 3 (scansite3.mit.edu). Receptor tyrosine kinase expression 
information was obtained from GeneCards (www.genecards.org) using the 
GeneCards ID numbers (GC id) GC10M121401 (FGFR2), GC04P001795 
(FGFR3), GC05P177086 (FGFR4), GC01P022710 (EphB2), GC07P116672 
(c-Met), and GC15P098648 (IGF-1R). 
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Results 
Identification of phosphorylated tyrosine 102 
 After having discovered in vitro lysine acetylation in BPV-1 E2 (Quinlan 
et al., 2012), we sought to determine whether other PTMs occurred on this 
protein in live cells. Two separate samples were prepared for mass 
spectrometric analysis. The first was obtained from C33a/E2 cells, derived from 
an HPV-negative human cervical cancer cell line but stably expressing the E2 
gene (You et al., 2004). The second was obtained from unaltered C33a cells 
transiently transfected with full-length BPV-1 E2 (amino acids [aa] 1-410). E2 
protein from both samples was purified by immunoprecipitation and analyzed 
by tandem mass spectrometry using a high-resolution LTQ orbitrap mass 
spectrometer. Data analysis included PTM identification as well as a confidence 
score (Table 2, Appendix). This approach detected the previously published 
phosphorylations at serines 298 and 301 (McBride et al., 1989), as well as 
acetylation at K112. Phosphorylation at tyrosine (Y) 102 (Figure 3.1) was of 
particular interest since tyrosine phosphorylation has not been detected for any 
E2 protein. Furthermore, this PTM was assigned the highest confidence score 
of any PTM in the report generated by Thermo’s Proteome DiscovererTM 
software, including those at the previously published sites (Table 2, Appendix). 
Y102 is in the center of the BPV-1 E2 transactivation domain (TAD, aa 1-210) 
between the three alpha-helices and beta sheet folds (Figure 3.2). While not 
conserved among all PVs, Y102 (or Y99, or Y103) occurs in 36 HPVs for which 
complete genomes are available, including the high-risk HPVs HPV-16 and 
HPV-31 (Table 4, Appendix). Tyrosine residues are also observed at these 
positions in 55 non-human PVs (Table 5, Appendix). 
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FIGURE 3.1 
 
 
 
 
 
 
Figure 3.1. Tyrosine 102 of BPV-1 E2 is phosphorylated in cells. Top, 
tandem mass spectrum of Y-102 phosphorylated peptide of BPV-1 E2. The 
target protein was immunoprecipitated from cell lysate using mouse 
monoclonal antibodies against BPV-1 E2. The dominant neutral loss of 
phosphoric acid, water, and ammonia from the precursor ion 
102YMSEPKR108 and sequence specific fragment ions were assigned by 
Proteome DiscovererTM. Other modified residues of this particular peptide 
are indicated in the table below the MS/MS spectrum (bottom). 
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FIGURE 3.2 
 
 
Figure 3.2. Y102 location in the transactivation domain (TAD) and 
mutagenesis. (A) The BPV-1 E2 TAD crystal structure 2JEU (Sanders et 
al., 2007) was identified in the Papillomavirus Episteme (PaVE, 
pave.niaid.nih.gov) and modified in Protein Workshop (rscsb.org/pdb) to 
highlight Y102 (ball and stick model, inset). N, amino terminus; C, carboxyl 
terminus. (B) The Agilent QuikChange II site-directed mutagenesis kit was 
used to generate tyrosine to phenylalanine (Y102F) and tyrosine to 
glutamate (Y102E) in the pCG-E2 construct. 1 μg each of wild type and 
mutant constructs (WT, YF, YE) were expressed in HEK293TT cells grown 
in 6-cm dishes, and cells were harvested for western blot 48 hours post-
transfection. mRFP-GFP was transfected in place of E2 as a negative 
control ((-)). The blot was probed for BPV-1 E2 with the mouse monoclonal 
antibody B201 (ascites). E2, full-length BPV-1 E2; *, nonspecific band. 
 
55 
    The phospho-mimetic mutant Y102E abrogates BPV-1 E2 mediated 
transcriptional activation 
 To investigate the potential functional significance of this PTM, we used 
site-directed mutagenesis to generate E2 constructs expressing a tyrosine to 
phenylalanine (Y102F) mutant, which cannot be phosphorylated at this site, and 
a tyrosine to glutamate (Y102E), which creates a negative charge similar to 
phosphotyrosine. E2 protein expression in HEK293TT cells was comparable to 
wild type (WT) for both mutants (Figure 3.2). We began activity studies with the 
tyrosine mutants by testing how these affected the ability of E2 to stimulate 
transcription. C33a cells were transfected with plasmids encoding WT BPV-1 
E2, Y102F, or Y102E along with a firefly luciferase reporter (pGL2-E2BS-Luc) 
containing four E2 binding sites upstream of an SV40 promoter (Kumar et al., 
2007). While Y102F stimulated luciferase expression at levels comparable to 
WT (38-fold above negative control), Y102E was inactive (Figure 3.3). 
However, Y102E protein levels in the C33a cells were lower than WT and 
Y102F (Figure 3.3). To ensure that these results were not due to lack of 
expression or cell type dependent differences, the experiments were repeated 
in CV-1 cells, an African green monkey kidney cell line. As in C33a, Y102F 
stimulated reporter transcription comparable to WT (35-fold above negative 
control), while Y102E failed to transactivate (Figure 3.4); its luciferase readout 
was comparable to that of the truncated BPV-1 E2R protein (aa 162-410), which 
exhibits low levels of transcription activation (Lace et al., 2012). In these cells, 
overexpression of Y102E resulted in protein levels comparable to WT and 
Y102F but did not restore transcriptional activation (Figure 3.4). 
 To determine whether the transcriptional defect of Y102E might be due 
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to altered co-factor binding, co-immunoprecipitation (co-IP) experiments were 
performed with BPV-1 E2 WT and mutants and different binding partners known 
to enhance E2-mediated transactivation. One of these binding partners, the 
chromatin modulator Brd4, has been shown in previous studies to interact via 
its extreme C-terminal domain (CTD, also C-terminal motif, CTM; Figure 3.5) 
with E2 from multiple PVs (You et al., 2004, You et al., 2005, Zheng et al., 2009, 
McPhillips et al., 2006). BPV-1 E2 WT and Y102 mutants were expressed in 
HEK293TT cells along with full-length Flag-tagged Brd4, and protein 
complexes were immunoprecipitated with mouse monoclonal anti-Flag (M2) 
conjugated beads. While WT and Y102F E2 co-immunoprecipitated with Brd4, 
Y102E was not (Figure 3.5). This was surprising since the Brd4 CTM is known 
to bind to the N-terminal alpha helices of the E2 TAD (Abbate et al., 2006), and 
contacts to the region of Y102 have not been previously described. To ascertain 
whether the observed effect was due to lack of Y102E binding to the CTM, 
GST-tagged CTM was substituted for full-length Brd4 in transfections, and 
complexes were captured on glutathione beads. Again, the same pattern 
appeared, with Y102E failing to associate (Figure 3.6). Cheng-Ming Chiang and 
colleagues reported distinct domains in Brd4 that undergo conformational 
changes to interact with p53 (Wu et al., 2013). We tested the basic interacting 
domain (BID) (Figure 3.5) for association with BPV-1 E2. Interestingly, GST-
BID pulled down WT, Y102F, and Y102E BPV-1 E2 proteins (Figure 3.6). Thus, 
Y102E fails to interact with the established E2 binding site of Brd4 but binds a 
novel site. 
 To ensure that the inability of Y102E to transactivate was not due to 
global disruption of the protein’s structure, we examined complex formation with 
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other known E2 binding partners, including Gps2 (also known as AMF1) and 
Tax1BP1. Gps2 has been found to stimulate transcription activation of E2 and 
recruit it to form a complex with the cofactor p300 (Breiding et al., 1997, Peng 
et al., 2000). Tax1BP1 (abbreviated TXBP) stabilizes protein levels of E2 and 
enhances its transactivation (Wang et al., 2009). BPV-1 E2 WT and mutant 
constructs were co-expressed with either hemagglutinin (HA)-tagged Gps2 or 
triple Flag-tagged (3xFlag) Tax1BP1, and complexes were captured with anti-
BPV-1 E2 antibody. Both Y102F and Y102E co-precipitated HA-Gps2 and 
3xFlag-Tax1BP1 (Figure 3.7). The E2R form was used as a negative control 
for Tax1BP1 association. 
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FIGURE 3.3 
 
 
 
 
Figure 3.3. The phospho-mimetic Y102E abrogates E2 transcriptional 
activation. (A) C33a cells were grown in 12-well dishes. Samples were 
transfected in triplicate wells with 50 ng/well pCG-E2 wild type or mutants 
(WT, Y102F, Y102E) or mRFP-GFP ((-)), as well as 75 ng/well pGL2-E2BS-
Luc. 48 hours post-transfection, cells were lysed on-plate with 100 μl Steady 
Glo reagent. Lysates were mixed with 100 μl DPBS and transferred to a 
white 96-well plate for luminescence detection using the Pherastar system. 
Student’s t test was used to compare samples to WT. RLU, relative light 
units; **, p<0.01; NS, not significant. Values are expressed as mean +/- 
SEM. (B) 1 μg each of wild type and mutant constructs (WT, YF, YE) or 
mRFP-GFP ((-)) were expressed in C33a cells grown in 6-cm dishes, and 
cells were harvested for western blot 48 hours post-transfection. The blot 
was probed for BPV-1 E2 with B201. E2, full-length BPV-1 E2; *, nonspecific 
band. 
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FIGURE 3.4 
 
 
 
 
Figure 3.4. Y102E is defective for transactivation in a second cell line. 
(A) CV-1 cells were cultured, transfected, and lysed as in Figure 3.3, but with 
10 ng/well E2, pCG-E2R (E2R, aa 162-410), or mRFP-GFP, plus wells with 
10 times the original amount of Y102E (100 ng/well, 10xYE). Student’s t test 
was used to compare samples to WT. RLU, relative light units; **, p<0.01; 
NS, not significant. Values are expressed as mean +/- SEM. (B) CV-1 cells 
were transfected and prepared for western blot as in Figure 3.3, with the 
addition of samples with 5 times Y102E (5xYE), 10 times Y102E (10xYE), 
or E2R. The blot was probed for BPV-1 E2 with B201. E2, full-length BPV-1 
E2; *, nonspecific band. 
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FIGURE 3.5 
 
 
 
 
 
Figure 3.5. Y102E does not bind full-length Brd4. (A) Domains of the 
Brd4 chromatin modulator protein, modified from (Wu et al., 2013). BD1 and 
BD2, bromodomains; BID, basic interacting domain; ET, extraterminal 
domain; CTM, C-terminal motif. (B) HEK293TT cells were grown on 6-cm 
dishes and transfected with 1 ug each mRFP-GFP (-), BPV-1 E2 wild type 
and mutants (WT, YF, YE), and Flag-tagged full length Brd4 (pVL-F:hBrd4) 
or pCI. Cells were harvested 48 hours post-transfection. 10% of each lysate 
was set aside for input, while remaining lysate was incubated at 4°C 
overnight with the anti-Flag mouse monoclonal antibody M2 conjugated to 
agarose beads. Samples were probed by western blot for Flag-Brd4 and 
BPV-1 E2 using M2 and B201, respectively. E2, full-length BPV-1 E2; *, 
nonspecific band. 
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FIGURE 3.6 
 
 
 
Figure 3.6. Y102E does not bind Brd4 CTM but associates with a novel 
E2 binding site. Samples were prepared as in Figure 3.5, with GST-tagged 
CTM substituted for full-length Brd4 in (A) and GST-BID substituted in (B). 
Complexes were pulled down with glutathione beads. Western blots were 
probed for GST with rabbit polyclonal antibody SD8 and for E2 with B201. 
*, nonspecific band. 
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FIGURE 3.7 
Figure 3.7. Y102 mutants associate with the transcription factors Gps2 
and Tax1BP1. (A) HEK293TT cells were grown on 6-cm dishes and 
transfected with 1 μg each mRFP-GFP (-), BPV-1 E2 wild type and mutants 
(WT, YF, YE) plus E2R, and hemagglutinin-tagged Gps2 (HA-Gps2, 
pHA:AMF1) or pCI. Cells were harvested 48 hours post-transfection. 5% of 
each lysate was set aside for input, while remaining lysate was incubated 
with protein sepharose A and G beads and the anti-BPV-1 E2 rabbit 
polyclonal antibody II-I at 4°C overnight. Western blots were probed for HA-
Gps2 and BPV-1 E2 using the mouse monoclonal anti-HA antibody HA-7 
and B201, respectively. (B) Samples were prepared as in (A), with 
p3XFLAG-CMV-7.1 Tax1BP1 substituted for pHA:AMF1. Cells were 
harvested 48 hours post-transfection. 10% of each lysate was set aside for 
input, while remaining lysate was used for immunoprecipitation as in (A). 
Western blots were probed with M2 and B201. Flag-TXBP, 3xFlag-
Tax1BP1. 
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    E2 Y102E cannot activate transient BPV-1 replication 
 E2 stimulates viral replication by recruiting E1 monomers to the viral 
origin of replication (ori). The ability of the Y102 mutants to stimulate transient 
replication of the viral ori was examined in a luciferase-based reporter assay. 
This method, developed by the Archambault lab for both BPV-1 and HPV-31 in 
C33a cells, requires co-transfection of plasmids encoding E2, the homologous 
E1 helicase, Renilla luciferase (internal control), and firefly luciferase (target 
replicon) (Fradet-Turcotte et al., 2010c, Gagnon et al., 2013). The firefly 
luciferase gene is constitutively expressed due to the presence of a CMV 
promoter. However, since the construct contains the BPV-1 ori, changes in 
plasmid copy number due to replication affect the amount of luciferase 
produced. Interestingly, Y102F-dependent luciferase activity was significantly 
increased above WT (Figure 3.8), In contrast, Y102E did not generate 
luminescence signal above baseline levels. To examine whether the Y102 
mutants are capable of binding E1, BPV-1 E1 and E2 were expressed in 
HEK293TT cells and immunoprecipitated with anti-E2 antibody. While Y102F 
co-precipitated E1 at levels comparable to WT, Y102E did not (Figure 3.9). 
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FIGURE 3.8 
 
 
 
 
 
 
 
 
Figure 3.8. Y102E fails to stimulate transient BPV-1 replication. C33a 
cells were grown in a 96-well clear bottom plate. Samples were transfected 
in 8 replicate wells with 10 ng/well pCG-E2 wild type or mutants (WT, Y102F, 
Y102E), E2R, or mRFP-GFP ((-)), as well as 10 ng/well pCG-E1, 2.5 ng/well 
pFLORI-BPV1 (firefly luciferase reporter), and 0.5 ng/well pRL (Renilla 
luciferase reporter). 72 hours post-transfection, cells were lysed on-plate 
with 30 μl Dual Glo reagent. Lysates were mixed with 30 μl DPBS and 
luminescence was detected using the Pherastar system. Student’s t test 
was used to compare samples to WT. F/R, firefly output (in relative light 
units) divided by Renilla output; **, p<0.01; ****, p<0.00001. Values are 
expressed as mean +/- SEM. 
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FIGURE 3.9 
 
 
 
 
 
 
 
 
 
Figure 3.9. Y102E is defective for association with the viral helicase E1. 
HEK293TT cells were grown on 6-cm dishes and transfected with 1 μg each 
mRFP-GFP (-), BPV-1 E2 wild type and mutants (WT, YF, YE), and BPV-1 
E1 or pCI. Cells were harvested 48 hours post-transfection. 10% of each 
lysate was set aside for input, while remaining lysate was incubated with 
protein sepharose A and G beads and II-I antibody at 4°C overnight. 
Western blots were probed for BPV-1 E1 and BPV-1 E2 using the rabbit 
polyclonal anti-E1 antibody 502-2 and B201, respectively. *, nonspecific 
band. 
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Y102 mutants localize to nuclei 
 The full-length E2 protein contains two putative nuclear localization 
signals, one in a basic region of the C-terminal DBD and another within the TAD 
(Zou et al., 2000, Skiadopoulos and McBride, 1996). Given the proximity of 
Y102 just amino terminal of the TAD NLS (aa 111-120), we sought to determine 
the localization of the Y102F and Y102E proteins. Immunofluorescence 
experiments were performed in CV-1 cells transfected with WT BPV-1 E2, 
Y102F, Y102E, or E2R as well as BPV-1 E1. A3 cells, murine fibroblast cells 
stably carrying BPV-1 genomes at high copy number (McBride and Howley, 
1991), were used as a positive control. CV-1 cells transfected with eGFP in 
place of E2 were used as a negative control. While the E2 distribution pattern 
in CV-1 cells with WT E2, Y102F, Y102E, and E2R was almost exclusively 
nuclear (similar to A3 cells), Y102E was mostly nuclear with some cytoplasmic 
distribution (Figure 3.10). 
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FIGURE 3.10 
 
 
 
Figure 3.10. Y102 mutants localize to nuclei. CV-1 cells were grown in 
12-well plates with 18-mm glass coverslips. A3 cells were grown under the 
same conditions as a positive control for E2 expression ((+)). CV-1 cells 
were transfected with 100 ng pCG-E1 and  100 ng pEGFP-C1 (eGFP, (-)), 
E2 wild type or mutants (WT, Y102F, Y102E), or E2R. 48 hours post CV-1 
transfection, cells were fixed and permeabilized, followed by incubation with 
B201 supernatant at 4°C overnight. Coverslips were washed, stained with 
Alexa Fluor 594 anti-mouse antibody, washed, and mounted onto glass 
slides using ProLong Gold with DAPI. Green, eGFP; red, BPV-1 E2; blue, 
DNA. White bar, 10 μm. All images taken in all three channels (green, red, 
blue) at 1000x magnification. 
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Receptor tyrosine kinases interact with E2 
 We utilized predictive software systems including NetPhos 2.0, Scansite 
3, and GPS 2.1 to inform our search for candidate kinases. NetPhos 2.0 
predicts the most likely phosphorylation sites in a protein; Y102 received the 
highest probability score of 0.968, followed by Y138 with 0.570. The other two 
algorithms predict kinases that might phosphorylate a given site. While Scansite 
3 predicted that the insulin receptor (INS-R) or insulin-like growth factor 
receptor (IGF-1R) would act on Y102 at its lowest threshold, GPS 2.1 predicted 
at its highest threshold that the acting kinase would be fibroblast growth factor 
receptor 3 (FGFR3). The receptor tyrosine kinases EphB2 and c-Met were also 
suggested to us as candidates (personal communication). mRNA transcripts of 
all of these tyrosine kinase receptors are expressed in skin and uterus 2- to 10-
fold above baseline by microarray analysis (www.genecards.org, biogps.org). 
Protein expression, however, is not significantly above baseline in skin, uterus, 
or cervix for any of these receptors (www.genecards.org).  After obtaining 
expression constructs for Flag-tagged FGFR3, the FGFR family members 
FGFR2 and FGFR4, and EphB2, we conducted co-immunoprecipitation 
experiments from HEK293TT lysates to determine whether BPV-1 E2 formed a 
complex with any of the kinases. Interestingly, BPV-1 E2 WT, Y102F, and 
Y102E immunoprecipitated all of these kinases (Figures 3.11, 3.12, 3.13, and 
3.14). We also tested HEK293TT lysates for complex formation between BPV-
1 E2 and endogenous c-Met or IGF-1R, but no co-immunoprecipitation was 
detected (Figures 3.15 and 3.16). All of the kinases probed by co-IP except for 
c-Met exist in a mostly cytoplasmic distribution in HEK293TT cells (Figure 3.17), 
though endogenous amounts are not high enough to detect by western blot 
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(Figures 3.12 and 3.13). Similar distributions were observed in HaCat cells, a 
spontaneously immortalized human keratinocyte line, and ID13 cells, a BPV-1 
transformed murine fibroblast line that maintains BPV-1 genomes at a low copy 
number (Figure 3.17). 
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FIGURE 3.11 
 
 
  
Figure 3.11. BPV-1 E2 associates with FGFR3. HEK293TT cells were 
grown on 6-cm dishes and transfected with 1 μg each mRFP-GFP (-), BPV-
1 E2 wild type and mutants (WT, YF, YE) plus E2R, and Flag-tagged FGFR3 
(pRK7-FGFR3-Flag) or pCI. Cells were harvested 48 hours post-
transfection. 5% of each lysate was set aside for input, while remaining 
lysate was incubated with protein sepharose A and G beads and II-I antibody 
at 4°C overnight. Western blots were probed for Flag-FGFR3 and BPV-1 E2 
using M2 and B201, respectively. *, nonspecific band. 
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FIGURE 3.12 
 
 
 
 
 
Figure 3.12. BPV-1 E2 associates with FGFR2. Samples were prepared 
as in Figure 3.11, with FGFR2 substituted for Flag-FGFR3. Western blots 
were probed with B201 and the rabbit anti-FGFR2/Bek antibody C-17. Inset 
box in input indicates longer exposure. 
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FIGURE 3.13 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. BPV-1 E2 associates with FGFR4. Samples were prepared 
as in Figure 3.11, with FGFR4 substituted for Flag-FGFR3. Western blots 
were probed with B201 and the rabbit anti-FGFR4 antibody C-16. 
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FIGURE 3.14 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. BPV-1 E2 associates with EphB2. Samples were prepared 
as in Figure 3.11, with EphB2 substituted for Flag-FGFR3. Western blots 
were probed with B201 and a mouse anti-EphB2 antibody. 
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FIGURE 3.15 
 
 
Figure 3.15. BPV-1 E2 does not associate with c-Met. HEK293TT cells 
were grown on 6-cm dishes and transfected with 1 μg each mRFP-GFP (-) 
or BPV-1 E2 wild type and mutants (WT, YF, YE) plus E2R. Cells were 
harvested 48 hours post-transfection. 5% of each lysate was set aside for 
input, while remaining lysate was incubated with protein sepharose A and G 
beads and II-I antibody at 4°C overnight. Western blots were probed for 
BPV-1 E2 using B201 and for endogenous receptor tyrosine kinases with 
rabbit anti-Met C-28. Labels in parentheses indicate that the protein was not 
identified. 
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FIGURE 3.16 
 
 
 
 
 
 
 
Figure 3.16. BPV-1 E2 does not associate with IGF-1R. Samples were 
prepared as in Figure 3.15 and probed for BPV-1 E2 using B201 and for 
endogenous receptor tyrosine kinases with rabbit anti-IGF-1Rβ C-20. Labels 
in parentheses indicate that the protein was not identified. 
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FIGURE 3.17 
 
Figure 3.17. Localization of fibroblast growth factor receptors in 
multiple cell lines. HEK293TT, HaCaT, and ID13 cells were grown in 
duplicate wells on 12-well plates with 18-mm glass coverslips. Cells were 
fixed and permeabilized, followed by incubation with anti-FGFR2/Bek C-17, 
anti-FGFR4 C-16, anti-EphB2, anti-Met C-28, or anti-IGF-1Rβ C20 at 4°C 
overnight. Coverslips were washed, stained with either Alexa Fluor 488 anti-
rabbit or AF 594 anti-mouse as appropriate, washed, and mounted onto 
glass slides using ProLong Gold with DAPI. Green, FGFR2, FGFR4, c-Met, 
or IGF-1R as labeled; red, EphB2; blue, DNA. White bar, 10 μm. All images 
taken at 1000x magnification. 
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Discussion and Future Directions, Part 1: Tyrosine Kinases in Productive 
Papillomavirus Infection 
 Here we report the identification and functional characterization of a 
novel tyrosine phosphorylation in BPV-1 E2. This residue at Y102 is conserved 
in 91 of the known PV species (Tables 4 and 5, Appendix), including many high-
risk HPVs. The detection of phospho-Y102 in two separate samples from live 
cells, the high confidence score which this PTM received by mass spectrometry 
analysis (Table 2, Appendix), and the conservation of Y102 among diverse PVs 
indicate that phosphorylation at this residue is important for one or more 
functions of the protein in vivo. 
 To begin investigations of its function, we generated at Y102 phospho-
defective (Tyr-Phe, Y102F) and phospho-mimetic (Tyr-Glu, Y102E) forms. 
Although the use of glutamate as a tyrosine phospho-mimetic is variably 
effective, there is a precedent in tyrosine kinase studies where Tyr-Glu mutants 
successfully mimic well-known effects of auto-phosphorylation of the enzyme 
(Zisch et al., 2000, Kassenbrock and Anderson, 2004). The BPV-1 E2 Y102F 
mutant retains WT function in a transcription assay. Notably, in transient BPV 
ori replication assays, Y102F activity was significantly increased over that of 
WT. In contrast, the Y102E mutant is completely defective for both transcription 
and replication (Figures 3.3, 3.4, and 3.8). Future studies to pinpoint the Y102E 
defect should include time-course assays (in case Y102E function is delayed) 
and comparison between samples treated with receptor tyrosine kinase ligands 
or inhibitors versus control. For the latter, however, global alterations in cell 
signaling may confound the results. 
The inability of Y102E to co-immunoprecipitate the BPV-1 E1 viral 
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helicase (Figure 3.9) likely explains its replication deficit. Y102F binds to E1 
and reproducibly demonstrated activity somewhat greater than WT, and it 
indeed appears to pull down more E1 than WT in Figure 3.9.  Our interpretation 
is that a fraction of WT E2 protein may undergo phosphorylation of Y102, 
thereby reducing its activity, while Y102F cannot undergo this negatively acting 
PTM. Indeed, the difference in replication stimulation between WT and Y102F 
in Figure 3.8 may reflect the size of the WT phospho-Y102 pool; with this pool 
eliminated by the Y102F mutation, E2 achieves its maximal activation. From 
these results we conclude that phosphorylation of this tyrosine is not required 
for the transcription or replication activities of E2. In contrast, the Y102E mutant 
is defective for the ability to induce transient viral DNA replication, which we 
attribute to its inability to co-immunoprecipitate the BPV-1 E1 helicase. 
The E1 binding surface of BPV-1 E2 spans the majority of the TAD 
(Baxter and McBride, 2005, Abbate et al., 2004) and includes the small α-helical 
loop on which Y102 resides (Figure 3.2). The Y102E mutation may prohibit 
binding of E2 to E1, or may disrupt the conformation of this loop as well as 
conformation of the N-terminal α-helices in the TAD described above. These α-
helices contain multiple residues important for E1 binding (Baxter and McBride, 
2005), and binding of transcriptional co-activators including Brd4 (Abbate et al., 
2006), Brm (Kumar et al., 2007) and TFIIB (aa 74-134) (Yao et al., 1998) 
Disruption of these structures would account for our IP and luciferase assay 
results. 
The transcriptional defect of Y102E is more complex to unravel. Both 
Y102E and Y102F co-immunoprecipitated with the E2 transcription enhancers 
Gps2/AMF1 and Tax1BP1 (Figure 3.7), which bind to the β-sheet region C-
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terminal of Y102 (Breiding et al., 1997, Wang et al., 2009) (see also Figure 3.2). 
Based on high amounts of Y102E on IP with very little Tax1BP1 co-precipitated 
(Figure 3.7), this mutant seems like a poor binding partner for this cofactor. 
Perhaps the mutant allows Tax1BP1 to recruit a stabilizing enzyme (such as 
the deubiquitinase A20) while minimizing direct interaction with Tax1BP1. The 
Gps2 and Tax1BP1 co-IP results are consistent with our earlier conclusion that 
association with these two factors is necessary but not sufficient to stimulate 
E2 dependent transactivation. 
Unlike Y102F, Y102E cannot associate with the full-length chromatin 
modulator Brd4 or the isolated Brd4 C-terminal motif (CTM) and does not 
appear to be stabilized (based on input) by the presence of CTM (Figures 3.5 
and 3.6). (Gps2 and Tax1BP1, in contrast, do seem to stabilize Y102E; see IP 
results, Figure 3.7.) In the co-crystal structure, the twenty amino acid Brd4 CTM 
peptide binds across the α-helices of the E2 TAD (Abbate et al., 2006) (see 
also Figure 2.1). If mutation of Y102 to glutamate induces a conformational 
change in the TAD, this could affect the α-helical region. It is also possible that 
the folding of the full Brd4 protein juxtaposes it in the vicinity of Tyr 102, such 
that phosphorylation of this residue destabilizes Brd4 interaction with the E2 α-
helices. E2 binding to the basic interacting domain (BID) of Brd4 was 
unexpected as the CTM is the only domain previously reported to interact with 
E2. The BID domain can bind to p53 (Wu et al., 2013) and to HPV E2 (C-M 
Chiang, personal communication). In Brd4:p53 interaction studies, BID was 
found to undergo a conformational change induced by serine phosphorylation 
within a different Brd4 domain (Wu et al., 2013). It is possible that such 
conformational changes regulate the association of Brd4 and E2, potentially 
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favoring E2’s interaction with one Brd4 domain over another. Such differential 
binding could change the functional outcome of E2:Brd4 association.  
 Because the Y102E mutant failed to activate both transcription and 
replication and could not associate with key mediators of these processes, we 
infer that phosphorylation at Y102 is inhibitory. Like the mutation to glutamate, 
phosphorylation at this site is expected to produce conformational changes that 
impair binding to co-factors, leading to inhibition of multiple functions. Based on 
our initial western blot of the Y102 mutants from HEK293TT lysates (Figure 3.2) 
and several co-IP experiments, we would not expect Y102E or phospho-Y102 
to be degraded more quickly than WT due to altered conformation. However, 
the decrement in Y102E expression in C33a cells (Figure 3.3) and in CV-1 cells 
without overexpression (Figure 3.4), as well as decreased expression 
compared to WT in certain co-IPs warrants further examination of the effect of 
this mutant on E2 stability. As with the CV-1 cells, Y102E overexpression (5 to 
10-fold) should be attempted in the C33a system. Co-IP studies assessing 
Y102E association with Gps2 and Tax1BP1 could also be performed in C33a 
and CV-1. Decreased interaction with these stabilizing cofactors compared with 
HEK293TT may explain the low expression of the mutant in these cells. Brd4 
interaction with mutants could also be examined in different cell lines, though 
the lack of association with Y102E even in HEK293TT suggests that Brd4 is not 
needed for stabilization of this mutant. Interestingly, in Figure 3.4, there is no 
apparent difference between Y10E levels in CV-1s with 5-fold versus 10-fold 
overexpression; this may be due to a maximum limit for transcription from this 
construct reached by the cellular machinery, or Y102E may have some 
transcription repression activity. HeLa repression assays, in which BPV-1 E2 is 
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expressed in HeLa cells and evaluated for its ability to decrease E6 and E7 
mRNA transcripts, would be helpful in assessing potential Y102E repression 
activity. 
Since dimerization of E2 is important for DNA binding, transcription, and 
replication (Moskaluk and Bastia, 1989, Prakash et al., 1992, Antson et al., 
2000, Cardenas-Mora et al., 2008), it is also possible that Y102 phosphorylation 
of one of the monomers prevents dimerization or changes conformation of the 
dimer so that E2 is inhibited in a dominant-negative manner if both 
phosphorylated and dephosphorylated forms of E2 co-exist within host cells. 
Cis or trans effects of Y102 phosphorylation on DNA binding and dimerization 
are unlikely since the DNA binding domain (DBD) is completely functional in the 
absence of the TAD, and there is no evidence for their physical association. 
However, chromatin immunoprecipitation (ChIP) of the Y102 mutants is still 
warranted to confirm this speculation. Altered subcellular localization 
preventing function can also be a consequence of PTMs, especially at or near 
a nuclear localization site (NLS). However, we did not observe phospho-Y102 
mis-localization to the extent that it affects E2 function since the Y102E mutant 
was predominately nuclear (Figure 3.10). 
We identified candidate kinases for Y102 phosphorylation and found that 
FGFR family members 2, 3, and 4 and the kinase EphB2 were co-
immunoprecipitated by BPV-1 E2 (Figures 3.11, 3.12, 3.13, and 3.14). This is 
the first evidence of any receptor tyrosine kinase in complex with E2. The 
kinase binding site could be in the TAD β-sheet region described above (see 
also Figure 3.2) since there is little difference between WT and Y102E co-
immunoprecipitation of receptors. Docking of a tyrosine kinase typically 
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involves a peptide region distinct from the targeted tyrosine, so mutating the 
active site would not necessarily affect binding. 
 In keratinocytes, the PV replicative cycle is closely linked to the host-cell 
life cycle, so kinase activity in these cells could be directly correlated with 
functional outcomes for a particular stage in viral infection. Multiple growth 
factor receptors including FGFR1 and IGF-1R have been found to translocate 
and act in the nucleus, where they could encounter E2 (Song et al., 2013). We 
expect that the kinase responsible for Y102 phosphorylation is most active in 
undifferentiated, basal keratinocytes, where viral replication and transcription 
occur at low levels (Figure 3.18). A study comparing the transcriptomes of 
keratinocytes in monolayer culture, skin, and reconstituted epidermis noted that 
growth factor receptors (such as the FGFRs, c-Met, and IGF-1R) and ephrin 
receptors (such as EphB2) were up-regulated in skin and reconstituted 
epidermis (Gazel et al., 2003). The data indicate that these receptors function 
in a differentiation-dependent context, though their expression in basal versus 
suprabasal versus superficial cells of the stratified epithelium remains unclear. 
We can, however, suggest that future studies of these receptors and E2 should 
include stratified epithelium, either from tissue samples or raft cultures. 
 Our data lead us to hypothesize the following scenario.  Y102 
phosphorylation accumulates in early infection (Figure 3.18) to limit replication 
and viral gene expression and thereby prevent a lytic infection which would 
trigger an immune response. As host cells differentiate, we expect that a 
tyrosine phosphatase restores Y102, thus activating E2 transcriptional and 
replication functions that result in viral genome amplification. 
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FIGURE 3.18 
 
 
 
  
Figure 3.18. Proposed model of E2 tyrosine phosphorylation in the 
context of the papillomavirus replicative cycle. Refer also to Figure 1.2. 
The kinase acting on Y102 is expected to be most active in basal 
keratinocytes (yellow triangle), where viral copy number is kept low in part 
through inhibition of E2 by phosphorylation (P-Y102, pink triangle). As host 
cells migrate upward and differentiate, dephosphorylated E2 is expected to 
predominate (Y102, blue triangle), permitting genome amplification. 
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Discussion and Future Directions, Part 2: Tyrosine Kinases in Cervical 
Cancer 
Although the majority of our studies focused on Y102 in BPV-1 E2, we 
have extended our focus to HPV-31. As one of the high-risk HPVs in which 
Y102 is conserved (Table 4, Appendix), HPV-31 interests us because of the 
potential for E2 PTMs to affect virally induced tumorigenesis. Although we could 
not detect P-Y102 in our HPV-31 E2 samples (Table 3, Appendix), we do not 
rule it out as a possibility since this PTM was predicted to occur by different 
software systems mentioned previously. Also, the IU Proteomics Core 
encountered difficulties in obtaining over 50% peptide coverage from their 
digests due to the unusually hydrophobic nature of the protein, so peptides 
containing Y102, let alone P-Y102, may have been present below the limits of 
detection. Nevertheless, the phosphorylation sites detected at serines and 
threonines in this protein (Table 3, Appendix) have not been reported 
previously, and may be worth exploring for their functional significance. T216, 
T220, and S266 are of particular interest since they received the highest 
confidence scores from the Core’s analysis software. 
Preliminary studies indicate that Y102E in HPV-31 E2 behaves similar 
to BPV-1 E2 Y102E in replication assays (Figure 3.19). Construction of cell 
lines from human foreskin keratinocytes (HFKs) stably expressing HPV-31 wild 
type or Y102 mutant genomes is currently in progress. Our goals are to not only 
observe differences in copy number during stable replication but to look for 
varying effects on copy number upon differentiation through the use of 
methylcellulose, calcium, or raft culture. Raft culture would be particularly 
informative since cells could also be used for immunohistochemistry to monitor 
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kinase distribution and activation in different keratinocyte layers. We expect 
that, while Y102F copy number would be higher than WT in undifferentiated 
keratinocytes, WT replication would escalate to Y102F levels upon 
differentiation. We do not expect Y102E to amplify its genome, though it may 
maintain a low copy number in undifferentiated cells. We also plan to initiate 
tyrosine kinase inhibitor studies in CIN612 cells (a human cell line stably 
expressing HPV-31) to compare viral copy number with and without treatment. 
It is possible that Y102E genomes could amplify upon differentiation, when E1 
is cleaved and activated (Moody et al., 2007, Morin et al., 2011). E1 may be 
sufficient to drive replication, and it could be recruited to the ori by cellular 
factors such as topoisomerase I (Hu et al., 2006) (see also Chapter 1) in the 
absence of E2 binding.  
Direct visualization of P-Y102 would be invaluable to elucidating the 
spatial and temporal distribution of this PTM. We have worked with Pacific 
Immunology (Ramona, California) to develop HPV-31 E2 antibodies specific to 
P-Y102. These antibodies were raised in New Zealand white rabbits against a 
peptide sequence of HPV-31 E2 containing phosphorylated or 
dephosphorylated E2, and the antibodies were affinity purified. Testing of the 
antibodies for specificity in western blot, co-IP, and immunofluorescence is 
currently under way. 
Findings from several laboratories over the last decade strongly suggest 
a role for kinases in HPV-associated cancers. HPV-16 E7 promotes 
overexpression of a cellular oncogene, cancerous inhibitor of protein 
phosphatase 2A (CIP2A), reducing c-Myc dephosphorylation on serine 62 by 
PP2A and thereby preventing its degradation (Liu et al., 2011). Conversely, 
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both low-risk (6 and 11) and high-risk (16 and 18) HPVs drive expression of the 
SHP-1 and SHP-2 tyrosine phosphatases (Tao et al., 2008), suggesting that 
these viruses are selective in their regulation of different PTMs in different 
signaling pathways. Indeed, tyrosine phosphorylation of annexin A1 and DNA-
PKcs, as well as other proteins, was found to be increased with advancing 
disease stage in cervical cancer (Robinson-Bennett et al., 2008). 
Receptor tyrosine kinases have been increasingly implicated in cervical 
and oropharyngeal cancer. Activating mutations in FGFR3 such as S249C were 
enriched in a subset of cervical cancers, and they were associated with 
differential gene expression and tissue phenotype compared to cancers with 
wild type FGFR3. This study indicated that lesions with high FGFR3 activity 
could be uniquely targeted for treatment in eligible patients (Rosty et al., 2005). 
Other RTKs, including EphB2 and IGF-1R, have also been found to play roles 
in HPV-associated cancers. EphB2 is upregulated in proportion to increasing 
cervical dysplasia (normal epithelium < high-grade squamous lesions < 
carcinoma), and overexpression of the kinase in cell culture models was found 
to induce epithelial to mesenchymal transition (Gao et al., 2014). IGF-1R was 
reported to act in oral cancer cells to down-regulate its own repressor, 
microRNA-99a, which has been described as a tumor suppressor gene (Yen et 
al., 2014). Together, these results suggest that RTKs can act as oncogenes in 
HPV-infected cells, and they have indeed been identified as such in other types 
of cancer (Chukkapalli et al., 2014, Salazar et al., 2014). 
Although E2 gene expression is lost in viral genome integration during 
tumorigenesis, it is possible that HPV oncoproteins prime cells for this event by 
inactivating E2 via up-regulation of tyrosine kinase activity (see Introduction to 
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this chapter). E2 phosphorylation would eliminate E1:E2 complex formation, 
which may protect the viral genome from nuclease activity and integration. E1 
would still be able to conduct replication, albeit less efficiently. E1-dependent 
replication, combined with unchecked E6 and E7 activity, may lead to increased 
aberrant replication, subsequent integration and complete loss of the E2 gene, 
and eventually host chromosomal instability and uncontrolled oncogene 
expression leading to cancer. 
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FIGURE 3.19 
 
 
 
  
Figure 3.19. Y102E fails to stimulate transient HPV-31 replication. C33a 
cells were grown in a 96-well clear bottom plate. Samples were transfected 
in 8 replicate wells with 10 ng/well codon-optimized Flag-HPV-31 E2 wild 
type or mutants (WT, Y102F, Y102E) or mRFP-GFP ((-)), as well as 10 
ng/well 3x-Flag-HPV31-E1 and 2.5 ng/well pFLORI31 (firefly luciferase 
reporter) (see Table 1, Appendix). 72 hours post-transfection, cells were 
lysed on-plate with 50 μl Steady Glo reagent. Lysates were mixed with 50 μl 
DPBS and luminescence was detected using the Pherastar system. RLU, 
relative light units. Values are expressed as mean +/- SEM. 
 
89 
CONCLUSIONS 
 Post-translational modification represents a dynamic means of 
controlling the timing and extent of a protein’s activity, and a multifunctional 
protein like papillomavirus E2 may require multiple forms of control. We 
hypothesized that post-translational modification of E2 controls the staging of 
the viral replicative cycle in concert with host-cell maturation and differentiation. 
We refined this hypothesis, clarifying that such control would manifest in 
differential binding to proteins which normally enhance E2 functions, including 
transactivation and replication. We demonstrated that BPV-1 E2 and HPV-31 
E2 are acetylated in cells, and we affirmed that one residue (K111) of a dilysine 
motif (K111-K112) is necessary for transcription activation. We propose that 
acetylation of this residue occurs late in papillomavirus infection to promote viral 
gene transcription. 
 We also detected a novel PTM, phosphorylation of tyrosine 102 in BPV-
1. An acetyl-mimetic point mutant at this site, Y102E, was defective for 
transcription activation and replication. This mutant also failed to bind the E2 
transcription co-factor Brd4 and the viral helicase E1, though it was able to 
associate with the transcription co-activators Gps2 and Tax1BP1. We also 
detected the first known association between BPV-1 E2 and receptor tyrosine 
kinases. We propose that phosphorylation at Y102 occurs early in infection to 
limit viral transcription and replication for the purposes of limiting copy number 
and evading the immune system. 
 Altogether, our results support our hypothesis since mutations at PTM 
sites not only had functional effects on E2 which could correspond to differential 
modification at certain stages of the viral replicative cycle (i.e. late in infection 
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for acetyl-K111, early in infection for P-Y102), but they also affected association 
with cellular co-factors such as Brd4, Gps2, and Tax1BP1. Future studies 
should seek to establish the physiological relevance of these PTMs in the 
context of infection, including whether these modifications occur simultaneously 
or are interdependent with one another for effective regulation of E2. Other 
PTMs detected in our mass spectrometry samples should also be examined for 
their relevance to papillomavirus biology, including involvement in switch 
mechanisms (i.e. two or more PTMs at the same site at different stages of the 
replicative cycle) or as multiple PTMs acting in concert to influence E2 function. 
 The present work underscores the value of studying post-translational 
modification in E2 – and potentially other viral proteins – to better understand 
papillomavirus infection. 
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TABLE 1 
 
Lab Plasmid Stocks 
HA-HPV31-E2 
HA-p300 
mRFP-GFP 
pBabe-Puro 
pcDNA3 Flag-Brd4 
pcDNA HA-AMF1 
pCI 
pCG-BPV1-E1 
pCG-BPV1-E2 
pCG-BPV1-E2 K111R 
pCG-BPV1-E2 K112R 
pCG-BPV1-E2 K111R/K112R 
pCG-VP16-E2 125 
pCMV 7.1 3x-Flag-Tax1BP1 
pGL2-E2BS-Luc 
pUC18 
 
Constructs Made for this Work 
HA-HPV31-E2 Y102F 
HA-HPV31-E2 Y102E 
HPV31 c-o Flag-HPV31-E2 
Y102F 
HPV31 c-o Flag-HPV31-E2 
Y102E 
pBR-HPV31 Y102F-E2 
pBR-HPV31 Y102E-E2 
pCG-BPV1-E2 K111Q 
pCG-BPV1-E2 K112Q 
pCG-BPV1-E2 Y102F 
pCG-BPV1-E2 Y102E 
pCG-BPV1-E2 WT-A3 
pCG-BPV1-E2 YF-A3 
pCG-BPV1-E2 YE-A3 
pCG-BPV1-E2 Y102A 
 
Gifts 
pCI-Rluc (Archambault) 
pFLORI-BPV1 (Archambault) 
pFLORI31 (Archambault) 
3x-Flag-HPV31-E1 
(Archambault) 
pGEX (GST) (Chiang) 
pGEX:hBrd4(524-579) (BID) 
(Chiang) 
pGEX:hBrd4(1224-1362) (CTM) 
(Chiang) 
pVL-F:hBrd4 (Chiang) 
pGEM-EGFR (Korc) 
HPV31 genome in pBR322min 
(Laimins) 
codon-optimized Flag-HPV31-E2 
(McBride) 
pcDNA3-EphB2 WT, chicken 
(Pasquale) 
pcDNA3-EphB2 KD K662R, 
chicken (Pasquale) 
pBabe-Puro IGF-1R (Spandau) 
pRK7-FGFR1 (Thompson) 
pRK7-FGFR2 (Thompson) 
pRK7-FGFR3-Flag WT 
(Thompson) 
pRK7-FGFR3-Flag K650E 
(Thompson) 
pRK7-FGFR4 (Thompson) 
 
Purchased 
pBabe-Puro HGF (Addgene) 
pLenti-Met GFP (Addgene) 
Table 1. Plasmid stocks used in experiments. Also included are constructs 
made for preliminary studies not described in the text, such as a BPV-1 E2 
Y102A mutant and Y102 mutants with the three serinealanine mutations that 
comprise the “A3” mutation set (YF-A3 and YE-A3). Individuals who generously 
donated plasmids include Jacques Archambault (McGill University); Cheng-
Ming Chiang (UT Southwestern); Murray Korc (Indiana University); Lou Laimins 
(Northwestern University); Alison McBride (NIAID); Elena Pasquale (Sanford-
Burnham Institute); Dan Spandau (Indiana University); and Leslie Thompson 
(UC Irvine). 
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TABLE 2 
 
BPV-1 E2 Residue Modification Times Observed (out 
of 3) 
S22 Phosphorylation**** 1 
S23 Phosphorylation**** 1 
K25 Acetylation 1 
Y32 Phosphorylation*** 1 
K48 Acetylation 2 
S62 Phosphorylation**** 1 
K70 Acetylation 1 
T97 Phosphorylation* 1 
S98 Phosphorylation* 1 
Y102 Phosphorylation**** 2 
S104 Phosphorylation**** 1 
K107 Acetylation 1 
K112 Acetylation 1 
S171 Phosphorylation** 1 
S181 Phosphorylation** 1 
T182 Phosphorylation** 1 
Y186 Phosphorylation** 1 
S187 Phosphorylation** 1 
S199 Phosphorylation** 1 
S200 Phosphorylation** 1 
T201 Phosphorylation* 1 
S202 Phosphorylation** 1 
S203 Phosphorylation** 1 
K226 Acetylation 1 
S275 Phosphorylation** 1 
S276 Phosphorylation** 1 
S277 Phosphorylation**** 1 
T283 Phosphorylation*** 1 
S298 Phosphorylation*** 3 
S301 Phosphorylation*** 3 
T302 Phosphorylation*** 1 
T313 Phosphorylation**** 1 
T314 Phosphorylation**** 1 
S332 Phosphorylation* 1 
T334 Phosphorylation*** 1 
K339 Acetylation 1 
Y341 Phosphorylation**** 1 
K346 Acetylation 1 
K347 Acetylation 1 
 
Table 2. Post-translational modifications detected for BPV-1 E2. According 
to the Thermo-Fisher Scientific Proteome DiscovererTM software (v1.3): *, low-
confidence score; **, mid-low confidence score; ***, mid-high confidence score; 
****, high confidence score. 
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TABLE 3 
 
HPV-31 E2 Residue Modification Times Observed (out 
of 3) 
K88 Acetylation 1 
K111 Acetylation 1 
T216 Phosphorylation**** 1 
T220 Phosphorylation*** 1 
T222 Phosphorylation** 1 
S266 Phosphorylation*** 1 
S269 Phosphorylation** 1 
S276 Phosphorylation* 1 
 
Table 3. Post-translational modifications detected for HPV-31 E2. See 
Table 2 legend for confidence scoring key. 
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TABLE 4 
 
HPV Type Genus Position of Tyrosine 
Residue 
Surrounding Sequence 
(-/+ 5 aa) 
6 α 99 LQETSYEMWQT 
8 β 102 TSIETYKNAPE 
11 α 99 LQDTSYEMWLT 
12 β 102 TSAETYNNVPE 
16 α 102 VSLEVYLTAPT 
19 β 102 TSAETYRSAPE 
25 β 102 TSTETYKSPPE 
26 α 99, 102 MRDTSYEMYMTEPK 
31 α 102 TSLELYTLTAPT 
32 α 99 LQETSYEMWHA 
35 α 103 TSIELYTTVPQ 
41 ν 105 TTKERYLAEPS 
49 β 102 TSLETYNAPPA 
51 α 99 MRETCYELWCV 
53 α 103 CESMWYTEPKQ 
69 α 99, 102 MRDTCYELYVTEPK 
76 β 102 TSLETYPTPPI 
82 α 99 MRDTCYELWGE 
85 α 102 TCQELYQTPPQ 
96 β 102 TSLETYRAPPV 
98 β 102 TSIETYKNAPE 
101 γ 99 LTDTSYELFMT 
108 γ 102 TSHELYTTPPE 
109 γ 102 TSFELYNAPPQ 
115 β 102 TSLETYRTPPS 
118 β 102 TSLETYKNAPE 
123 γ 102 TSFELYNSSPQ 
124 β 102 TSLETYRNQPE 
134 γ 102 TSLELYNTEPE 
139 γ 102 TSFEVYNAAPF 
152 β 102 TSLETYRNRPE 
155 γ 99, 102 MQDTSYEIYSAAPK 
156 γ 103 SAELTYTAPRN 
170 γ 99, 102 LQDTSYEAYTSAPE 
174 β 99 LVQTSYETFRS 
175 γ 103 STEIIYTPPRN 
 
Table 4. Tyrosine 102 conservation among human papillomaviruses. 
Viruses are listed by type, with genus and presence of Y102 or an analogous 
site (e.g. Y99, Y103) listed. Amino acid sequence surrounding the tyrosine(s) 
of interest (bold) is also provided. Genus and sequence information were 
obtained from the Papillomavirus Episteme (pave.niaid.nih.gov). 
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TABLE 5 
 
PV Type Genus Position of Tyrosine 
Residue 
Context Sequence 
AaPV1 δ 102 SWERYQ 
AsPV1 π 102 SLELYK 
BPV1 δ 102 SWDRYM 
BPV2 δ 102 SWDRYM 
BPV5 ε 102 SHERYK 
BPV8 ε 102 SHERYK 
BPV13 δ 102 SWDRYM 
BgPV1 δ 102 SWDRYI 
BpPV1 Dyo-κ 99, 102 SYETYV 
CPV3 χ 99 SYERWT 
CPV5 χ 99 SYERWM 
CcPV1 Dyo-ζ 99 QYQLVM 
CcaPV1 δ 102 SWDRYV 
CdPV1 δ 99, 102 SYETYS 
CdPV2 δ 99 SYECFS 
ChPV1 φ 102 SSMTYL 
CmPV1 Dyo-ζ 99 QYSLVM 
DdPV1 υ 102 SHEMYT 
EaPV1 - 102 SWDRYA 
EcPV2 Dyo-ι 102 SREMYA 
EcPV3 Dyo-ρ 102 SKETYR 
EcPV4 Dyo-ι 99 SYELFK 
EdPV1 σ 102 TLERYL 
EhelPV1 - 102 SWELYK 
EserPV2 - 102 SLEKYS 
FlPV1 Dyo-ε 102 SPTVYK 
MaPV1 π 102 SLELYE 
McPV2 π 102 SLEMYE 
MfPV5 α 103 SLEMWY 
MmuPV1 π 102 SREMYD 
MnPV1 ι 102 SREMYM 
MpPV1 τ 102 SLELYL 
MscPV1 - 102 SREKYL 
OaPV1 δ 99, 102 SYERYL 
OaPV2 δ 99, 102 SYERYL 
OvPV1 δ 102 SWGRYQ 
PmPV1 ι 102 SREMYM 
PphPV1 ο 102 SKEMYA 
PphPV2 υ 102 TFSMYM 
PphPV4 Dyo-π 102 SSEMYM 
PsPV1 ο 102 SHDMYM 
PsuPV1 π 102 SVEVYE 
RaPV1 ψ 102 SRENYM 
RnPV1 π 102 SIEMYE 
97 
RnPV2 ι 102 SRDMYL 
RtPV1 δ 102 SWDRYQ 
SsPV1 Dyo-δ 102 TWESYR 
TmPV2 ρ 102 SEERYK 
TtPV2 υ 102 SKDMYM 
TtPV3 υ 99 SYEMFQ 
TtPV4 υ 102 SHELYT 
TtPV5 ο 102 SIELYD 
TtPV7 υ 102 SHELYM 
UmPV1 ω 102 SVELYE 
ZcPV1 Dyo-ν 102 SWERYT 
 
Table 5. Tyrosine 102 conservation among non-human papillomaviruses. 
Information is organized as in Table 4 and was also obtained from the 
Papillomavirus Episteme. 
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